Document:

Exhibit

Exhibit 10.1

INVESTMENT AGREEMENT

THIS INVESTMENT AGREEMENT (this “Agreement”), dated as of March 13, 2017, is made by and among MVB Financial Corp. (the “Company”), and Larry F. Mazza, the Chief Executive Officer of the Company (the “Investor”).

WHEREAS, the Company proposes to conduct a rights offering (the “Rights Offering”) by distributing, at no charge, to each holder of record as of the Record Date (as defined below) of shares (“Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), one non-transferable right (the “Rights”), for each Share held by such shareholder, to purchase Shares which Rights, if exercised in full by each holder of record as of the Record Date, will provide gross proceeds to the Company of approximately $5.0 million (the “Aggregate Offering Amount”);
WHEREAS, each holder of a whole Right will be entitled to purchase up to its pro rata portion of the 434,783 Shares (the “Offered Shares”) offered in the Rights Offering (the “Basic Subscription Right”) at a price equal to $11.50 per Share (as appropriately adjusted for any stock split, combination, reorganization, recapitalization, stock dividend, stock distribution or similar event, the “Exercise Price”);
WHEREAS, each holder of Rights who exercises all of its Rights will be entitled, on a pro rata basis, to subscribe for additional Shares at the Exercise Price (the “Over-Subscription Right”), to the extent that other holders of Rights do not exercise all of their respective Basic Subscription Rights in full, up to that number of Shares equal to 434,783 minus the number of Shares such holder was entitled to purchase pursuant to the its Basic Subscription Right;
WHEREAS, in order to facilitate the Rights Offering, the Investor has agreed to subscribe for and purchase, at the Exercise Price, upon expiration of the Rights Offering, that number of Shares, if any, equal to the amount by which 100,000 exceeds the number of Shares purchased by the Investor pursuant to the exercise of his Basic Subscription Right and Over-Subscription Right upon the terms and subject to the conditions set forth herein;
WHEREAS, the Board of Directors has approved the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Shares to the Investor on the terms hereof).
NOW, THEREFORE, in consideration of the mutual promises, agreements, representations, warranties and covenants contained herein, each of the parties hereto hereby agrees as follows:
1.Rights Offering.
(a)    On the terms and subject to the conditions set forth herein, the Company will distribute, at no charge, one Right to each holder of record of Common Stock (each, an “Eligible Holder”) for each share of Common Stock held by such holder as of the close of business on a record date to be determined by the Board of Directors (the “Record Date”).  Each such Right shall be non-transferable.  Each whole Right will entitle the holder thereof to purchase, at the election of the holder thereof, 0.04349 of a Share at the Exercise Price.  Each fractional Right will be rounded down to the nearest whole number, and fractional Rights will not entitle any holder to purchase any Shares.  No fractional Shares will be issued in the Rights Offering.
(b)    The Basic Subscription Right and the Over-Subscription Right may be exercised during a period (the “Rights Exercise Period”) commencing on the date on which Rights are issued to Eligible Holders (the “Rights Offering Commencement Date”) and ending at 5:00 p.m. Eastern Time on a Business Day that shall not be less than fifteen (15) days after the Rights Offering Commencement Date. “Business Day” means each Monday, Tuesday, Wednesday, Thursday and Friday that is not a day on which banking institutions in New York City are generally authorized or obligated by law or executive order to close.
(c)    If the Investor is unable to acquire at least 100,000 Shares under in the Rights Offering having an aggregate purchase price of $1,150,000, the Company shall issue at the Closing additional Shares, if any, to the Investor 

1

equal to the amount by which 100,000 exceeds the number of Shares purchased by the Investor pursuant to the exercise of his Basic Subscription Right and Oversubscription Right at a purchase price equal to the Exercise Price. The parties acknowledge and agree that the number of additional Shares purchased by the Investor pursuant to this Section 1(c) shall have no effect on the number of Shares to be sold in the Rights Offering.
(d)    The closing of the purchase of the additional Shares, if any, to be purchased by the Investor hereunder (the “Closing”) will occur at 10:00 a.m., New York City time, on the fourth (4th) Business Day following the expiration of the Rights Offering (the “Closing Date”).  Delivery to the Investor of the additional Shares, if any, acquired hereunder (the “Investor Shares”) will be made by the Company to account of the Investor.  The documents to be delivered on the Closing Date by or on behalf of the parties hereto and the Investor Shares will be delivered at the offices of Squire Patton Boggs (US) LLP, Cincinnati, Ohio, on the Closing Date.
(e)    All Investor Shares will be delivered with any and all issue, stamp, transfer, sales and use, or similar Taxes or duties payable in connection with such delivery duly paid by the Company.
2.    Representations and Warranties of the Investor. The Investor represents and warrants to the Company as follows:
(a)    This Agreement is valid, binding and enforceable against the Investor in accordance with its terms; subject, as to enforcement, to bankruptcy, insolvency, reorganization, fraudulent conveyance and other laws of general applicability relating to or affecting creditors’ rights and to general equity principals.
(b)    The Investor is not in default under any agreement, indenture or instrument to which the Investor is a party, the effect of which violation or default could reasonably be expected to have a material adverse effect on the Investor, and the execution, delivery and performance of this Agreement by the Investor and the consummation of the transactions contemplated hereby will not conflict with, or constitute a breach of, or default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the assets of the Investor pursuant to the terms of any agreement, indenture or instrument to which the Investor is a party which lien, charge or encumbrance could reasonably be expected to have a material adverse effect on the Investor, or any order, rule or regulation of any court or governmental agency having jurisdiction over the Investor or any of its property; and, no consent, authorization or order of, or filing or registration with, any court or governmental agency is required for the execution, delivery and performance of this Agreement other than those required of the Company in connection with the Rights Offering.
(c)    The Investor is an “accredited investor” as that term is defined in Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”).
(d)    The Investor is familiar with the business of the Company. The Investor has knowledge and experience in financial and business matters; is familiar with the investments of the type that it is contemplated by this Agreement, is fully aware of the problems and risks involved in making an investment of this type, and is capable of evaluating the merits and risks of this investment. The Investor acknowledges that, prior to executing this Agreement, he has had the opportunity to ask questions of and receive answers or obtain additional information from a representative of the Company concerning the financial and other affairs of the Company.
(e)    The Investor has available sufficient funds to pay the purchase price for the Shares in the Rights Offering and the Investment Shares, if any, in accordance with the terms of the Rights Offering and this Agreement, and the evidence thereof provided to the Company’s Board of Directors is accurate and complete.
(f)    The Investor is acquiring the shares for his own account, with the intention of holding such shares for investment and with no present intention of participating, directly or indirectly, in a distribution of the shares; provided, however, that Investor may transfer shares to trusts for the benefit of the children of the Investor.
(g)    The Investor has no need for liquidity in the Investor’s investment in the Investor Shares and understands that there are restrictions on the subsequent resale or other transfer of the Investor Shares.

2

(h)    The Investor understands that the Investor Shares purchased by the Investor are deemed “restricted securities” as such term is defined in Rule 144 promulgated under the Securities Act (“Rule 144”) and that the Shares purchased by the Investor in the Company’s Rights Offering are “control” shares subject to the conditions of Rule 144, and they may not be sold, assigned, conveyed, pledged, hypothecated or otherwise transferred by a holder thereof except pursuant to Rule 144, pursuant to an effective registration statement registering the Investor Shares and the Shares purchased by the Investor in the Rights Offering under the Securities Act or in a transaction otherwise exempt from registration under the Securities Act. Further, the following legends (or similar language) shall be placed on the certificate(s) representing the shares of Common Stock:
THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, UNDER THE SECURITIES LAWS OF ANY STATE OR ARE HELD BY AN AFFILIATE OF THE ISSUER. THEY MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT COVERING THESE SECURITIES UNDER THE SAID ACT OR LAWS, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT REGISTRATION IS NOT REQUIRED THEREUNDER.
		
	3.
	Representations and Warranties of the Company.

(a)    The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of West Virginia, with full power and authority to perform its obligations under this Agreement.
(b)    This Agreement has been duly and validly authorized, executed and delivered by the Company. This Agreement is valid, binding and enforceable against the Company in accordance with its terms, subject, as to enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting creditors’ rights and to general equity principals.
(c)    All of the shares of Common Stock to be issued pursuant to this Agreement will have been duly authorized for issuance prior to the Closing, and, when issued and distributed in connection with the Rights Offering  and this Agreement, will be validly issued, fully paid and non-assessable; and none of such shares of Common Stock will have been issued in violation of the preemptive rights of any security holders of the Company arising as a matter of law or under or pursuant to the Company’s Certificate of Incorporation, as amended, the Company’s Bylaws, as amended, or any material agreement or instrument to which the Company is a party or by which it is bound.
(d)    The Company is not in violation of its Articles of Incorporation, as amended, or Bylaws, as amended, or in default under any agreement, indenture or instrument to which the Company is a party, the effect of which violation or default could reasonably be expected to have a material adverse effect on the Company (a “Material Adverse Effect”), and the execution, delivery and performance of this Agreement by the Company and the consummation of the transactions contemplated hereby will not conflict with, or constitute a breach of, or default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the assets of the Company pursuant to the terms of any agreement, indenture or instrument to which the Company is a party which lien, charge or encumbrance could reasonably be expected to have a Material Adverse Effect on the Company, or result in a violation of the Certificate of Incorporation or Bylaws of the Company or any order, rule or regulation of any court or governmental agency having jurisdiction over the Company or any of its property; and, except as required by the Securities Act, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and applicable state securities laws, no consent, authorization or order of, or filing or registration with, any court or governmental agency is required for the execution, delivery and performance of this Agreement.
4.    Covenants.
(a)    Neither the Company nor the Investor shall issue any public announcement, statement or other disclosure with respect to this Agreement or the transactions contemplated hereby without the prior consent of the other party hereto, which consent shall not be unreasonably withheld or delayed, except if such public announcement, statement or other disclosure is required by applicable law or applicable stock market regulations, in which case the 

3

disclosing party shall consult in advance with respect to such disclosure with the other parties to the extent reasonably practicable.
(b)    The Investor will not sell or otherwise transfer, publicly or privately, any of the Investor Shares acquired by him for six-months following the closing of the Rights Offering.
5.    Termination.  This Agreement may be terminated and the transactions contemplated hereby may be abandoned prior to the Closing Date by mutual written consent of the Company, on the one hand, and the Investor, on the other hand.
6.    Notices.  All notices and other communications in connection with this Agreement will be in writing and will be deemed given (and will be deemed to have been duly given upon receipt) if delivered personally, sent via electronic transmission or facsimile (with confirmation), mailed by registered or certified mail (return receipt requested) or delivered by an express courier (with confirmation) to the parties at the following addresses (or at such other address for a party as will be specified by like notice):
(a)    If to:
MVB Financial Corp. 
301 Virginia Avenue 
Fairmont WV 26554-2777 

with a copy (which shall not constitute notice) to:
 
Squire Patton Boggs (US) LLP
221 E. Fourth St., Suite 2900
Cincinnati, Ohio  45202 
Attention: James J. Barresi
Email:  James.Barresi@squirepb.com

(b)    If to:
Larry F. Mazza
c/o MVB Financial Corp. 
301 Virginia Avenue 
Fairmont WV 26554-2777
 

7.    Assignment; Third Party Beneficiaries.  Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned by any of the parties (whether by operation of law or otherwise) without the prior written consent of the other parties.
8.    Prior Negotiations; Entire Agreement.  This Agreement (including the agreements attached as exhibits to and the documents and instruments referred to in this Agreement) constitutes the entire agreement of the parties and supersedes all prior agreements, arrangements or understandings, whether written or oral, between the parties with respect to the subject matter of this Agreement, except that the parties hereto acknowledge that any confidentiality agreements heretofore executed among the parties will continue in full force and effect.
9.    Counterparts.  This Agreement may be executed in any number of counterparts, all of which will be considered one and the same agreement and will become effective when counterparts have been signed by each of the parties and delivered to the other party (including via facsimile or other electronic transmission), it being understood that each party need not sign the same counterpart.

4

10.    Waivers and Amendments.  This Agreement may be amended, modified, superseded, cancelled, renewed or extended, and the terms and conditions of this Agreement may be waived, only by a written instrument signed by all the parties or, in the case of a waiver, by the party waiving compliance.  No delay on the part of any party in exercising any right, power or privilege pursuant to this Agreement will operate as a waiver thereof, nor will any waiver on the part of any party of any right, power or privilege pursuant to this Agreement, nor will any single or partial exercise of any right, power or privilege pursuant to this Agreement, preclude any other or further exercise thereof or the exercise of any other right, power or privilege pursuant to this Agreement.  The rights and remedies provided pursuant to this Agreement are cumulative and are not exclusive of any rights or remedies which any party otherwise may have at law or in equity.
11.    Adjustment to Shares.  If, prior to the Closing Date, the Company effects a reclassification, stock split (including a reverse stock split), stock dividend or distribution, recapitalization, merger, issuer tender or exchange offer, or other similar transaction with respect to any shares of its capital stock, references to the numbers of such shares and the prices therefore shall be equitably adjusted to reflect such change and, as adjusted, shall, from and after the date of such event, be subject to further adjustment in accordance herewith.
12.    Headings.  The headings in this Agreement are for reference purposes only and will not in any way affect the meaning or interpretation of this Agreement.
 
[Signature Page Follows]

5

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed by their respective officers thereunto duly authorized, all as of the date first written above.
 
	
			
	 
	MVB FINANCIAL CORP.

	 
	 

	 
	/s/ Donald T. Robinson

	 
	 
	 

	 
	 Name: Donald T. Robinson
 Title: Chief Financial Officer

	 
	

/s/ Larry F. Mazza

	 
	Larry F. Mazza

6Execution
Version

 

CONTRIBUTION
AGREEMENT TO THE PROPERTY OF TRUST F/2868 (TWO THOUSAND EIGHT HUNDRED SIXTY EIGHT) (THIS “AGREEMENT”),
dated March 10, 2017, pursuant to the following recitals, representations and clauses, by and between each of:

 

PARTIES

 

	 	I.	MANUEL
    COSME ODABACHIAN (“MCO”), on his own behalf; 
	 	 	 
	 	II.	CARLOS
    FERNANDO ALAMAN VOLNIE (“CAV”), on his own behalf, and 
	 	 	 
	 	III.	ONCBIOMUNE
    PHARMACEUTICALS, INC., a Nevada corporation (“OBMP”), represented herein by Andrew Albert Kucharchuk.

 

RECITALS

 

WHEREAS,
the parties hereto, simultaneously to the execution hereof, have entered into a trust agreement, dated March 10, 2017, identified
as No. F/2868 (two thousand eight hundred sixty eight) (the “Trust” or “Trust Agreement”),
whereby MCO, CAV and OBMP acted in their capacity as trustors and beneficiaries, and Banco Actinver, S.A., Institución
de Banca Múltiple, Grupo Financiero Actinver (the “Trustee”), acted in its capacity as trustee, for
the purpose of establishing a vehicle for a business venture between MCO, CAV and OBMP for the development and commercialization
of OBMP’s vaccine technology and other OBMP cancer technologies in Mexico, as well as in connection with expediting clinical
development and marketing of OBMP’s therapeutic candidates in Mexico and other countries and territories in Latin America.

 

WHEREAS,
MCO and CAV, along with certain other shareholders of OBMP, simultaneously to the execution hereof, have entered into a shareholders’
agreement in their capacity as direct or indirect shareholders of OBMP (as applicable) (the “Shareholders’ Agreement”
and together with the Trust Agreement, the “Related Agreements”).

 

NOW
THEREFORE, based on the foregoing premises and the representations, warranties, covenants and agreements set forth herein, the
parties hereby agree as follows:

 

CLAUSES

 

CLAUSE
I: DEFINITIONS AND INTERPRETATION

 

Clause
1.1 Defined Terms. In this Agreement, capitalized terms used herein shall have the following meaning, in the understanding
that capitalized terms not defined herein shall have the respective meanings assigned to such terms in the Trust Agreement.

 

“Affiliate”
means, in connection with any Person (i) any other Person that, directly or indirectly, Controls, is Controlled by, or is under
common Control with, such Person, or (ii) any other Person that owns or controls 50% (fifty percent) or more of the shares or
membership interests issued, and with voting rights, of such Person, or (iii) any officer, managing member, executive, or manager
of such Person, or (iv) any other Person that is an officer, executive, managing member, manager, or holds 50% (fifty percent)
or more of the shares or membership interests with voting rights of any of the Persons mentioned in subsections (i) to (iii) of
this definition.

 

    	 	 	 

    	 		 

    

 

“Agreement”
has the meaning set forth in the preamble.

 

“CAV”
has the meaning set forth under Parties.

 

“Closing”
has the meaning set forth in Clause 2.2.

 

“Confidential
Information” has the meaning set forth in Clause 5.1(b).

 

“Control”
means the authority to determine the management, and the policies of a Person, directly or indirectly, whether through holding
securities or membership interests with voting rights, through an agreement, or otherwise.

 

“Dollars”
means the legal currency of the United States of America.

 

“Excluded
Business” or “Excluded Businesses” has the meaning set forth in Clause 5.2(a).

 

“Excluded
Contracts” has the meaning set forth in Exhibit “A”.

 

“General
Indemnity Survival Period” has the meaning set forth in Clause 4.3(a)(iv).

 

“Governmental
Authority” means any Federal, State, Municipal, or local authority in the United States of America or Mexico.

 

“IFRS”
shall mean International Financial Reporting Standards.

 

“Indemnified
Person” means the person granting the indemnities referred to in Clause IV hereof, which shall be either of the
following, as applicable: (i) MCO and CAV (jointly), or (ii) OBMP.

 

“Indemnifying
Party” means the person granting the indemnities referred to in Clause IV hereof, which shall be either the MCO
and CAV (jointly and severally in accordance with their respective pro rata percentage of the OBMP Shares they both hold) or OBMP,
as applicable

 

“LGSM”
means the General Law of Companies (Ley General de Sociedades Mercantiles), as amended, or supplemented from time to time.

 

“LIC”
means the Credit Institutions Law (Ley de Instituciones de Crédito), as amended, or supplemented from time to time.

 

“Losses”
has the meaning set forth in Clause 4.1(a).

 

    	 	2	 

    	 		 

    

 

“Material
Adverse Effect” means any adverse effect upon or change in the condition (financial or otherwise) of Vitel Mexico and/or
OBMP, or on their ability to continue or conduct the Vitel Business or the OBMP Business, as applicable, which is Material.

 

“Material
Contract” means any agreement or contract (i) involving aggregate payments to or by Vitel or OBMP, as applicable, in
excess of US$50,000.00 (fifty thousand Dollars 00/100); or (ii) which is outside the Vitel Business or the OBMP Business, as applicable;
or (iii) containing covenants limiting the ability of Vitel or OBMP, as applicable, to compete in any line of business with any
Person or in any area or territory; or (iv) which binds Vitel or OBMP, as applicable, to a term of more than one (1) year; or
(v) imposes a lien or encumbrance on the assets of Vitel or OBMP, or on the Vitel Shares or the OBMP Shares. All Material Contracts
are listed in Schedule I (q) and Schedule II (r) hereof, except in the case of OBMP, those contracts filed with
the Securities and Exchange Commission in the United States of America as material contracts, which are not listed separately.

 

“Material”
or “Materially” means, when used to qualify an event, action, condition, omission, or representation, warranty,
covenant or other provision of this Agreement, any circumstance, condition, event, series of substantially similar or substantially
related circumstances, conditions or events, that has, in the aggregate, a cost or expense in excess of US$50,000.00 (fifty thousand
Dollars 00/100).

 

“MCO”
has the meaning set forth under Parties.

 

“Mexico”
means the United Mexican States.

 

“OBMP”
has the meaning set forth under Parties.

 

“OBMP
Business” means pharmaceutical development and sales.

 

“OBMP
Governmental Permit” has the meaning set forth in Clause 3.2 (x).

 

“OBMP
Indemnified Person” has the meaning set forth in Clause 4.1(a).

 

“OBMP
IP Rights” has the meaning set forth in Clause 3.2 (gg).

 

“OBMP’s
Knowledge” means the actual knowledge of Jonathan F. Head or Andrew A. Kucharchuk.

 

“OBMP
Licensed IP Rights” has the meaning set forth in Clause 3.2 (gg).

 

“OBMP
Mexico” means Oncbiomune Mexico, S.A. de C.V., a Mexican variable stock corporation, 50% (fifty per cent) of which is
owned by OBMP and 50% (fifty per cent) is owned by Vitel.

 

“OBMP
Owned IP Rights” has the meaning set forth in Clause 3.2 (gg).

 

“OBMP
Pipeline” shall mean the following:

 

    	 	3	 

    	 		 

    

 

(a)
Ovcavax® Ovarian Cancer;

 

(b)
PA-OBC – Breast Cancer; 

 

(c)
PGT-OBM – Renal Cancer; and

 

(d)
Any other product under development, developed or to be developed by OBMP and/or by Dr. Jonathan F. Head in collaboration, under
contract or under any other type of business relationship with OBMP or with any OBMP related Person.

 

“OBMP
Products” shall mean the following:

 

(a)
Proscavax® Prostate Cancer;

 

(b)
OBMP Pipeline; and

 

(c)
OBMP vaccine technology, OBMP cancer technologies for the treatment of prostate, ovarian and various other types of cancer and
any other technology for medical treatment, drug or medical treatment owned by OBMP or by any OBMP related Person or that use
or are based on the technology included in the OBMP IP Rights, the OBMP Licensed IP Rights, the OBMP Owned Rights or the OBMP
Registered IP Rights.

 

“OBMP
Registered IP Rights” has the meaning set forth in Clause 3.2 (kk).

 

“OBMP
Shares” means 61,158,013 shares of common stock and 2,107,681 shares of Series B preferred stock of OBMP.

 

“Person”
means any natural or legal person, trust, joint venture, partnership or company, Governmental Authority, or any other entity of
any kind, with or without its own legal capacity.

 

“Related
Agreements” has the meaning set forth in the recitals,

 

“Restricted
Business” has the meaning set forth in Clause 5.2(a).

 

“ROW
Opportunity” has the meaning set forth in Clause 5.2(b).

 

“Shareholders’
Agreement” has the meaning set forth in the recitals, as the same may be amended, whether in whole or in part, supplemented,
or otherwise altered, renewed, or extended at any time.

 

“Third
Party Claim” has the meaning set forth in Clause 4.4(a).

 

“Transactions”
has the meaning set forth in Clause 2.2.

 

“Trust”
or “Trust Agreement” has the meaning set forth in the recitals.

 

“Trustee”
has the meaning set forth under Parties.

 

“U.S.
GAAP” means generally accepted accounting principles in the United States of America.

 

    	 	4	 

    	 		 

    

 

“Vitel”
means Vitel Laboratorios, S.A. de C.V., a Mexican variable stock corporation.

 

“Vitel
Business” means pharmaceutical development and sales.

 

“Vitel
Governmental Permit” has the meaning set forth in Clause 3.1 (w).

 

“Vitel
Indemnified Person” has the meaning set forth in Clause 4.2.

 

“Vitel
IP Rights” has the meaning set forth in Clause 3.1 (ff).

 

“Vitel
Licensed IP Rights” has the meaning set forth in Clause 3.1 (ff).

 

“Vitel
Owned IP Rights” has the meaning set forth in Clause 3.1 (ff).

 

“Vitel
Products” shall mean the following:

 

(a)
Any other product under development, developed or to be developed by Vitel that use or are based on any Vitel IP Rights, Vitel
Licensed IP Rights, the Vitel Owned IP Rights and the Vitel Registered IP Rights, or under contract or under any other type of
business relationship involving a Material Contract, the Vitel IP Rights, the Vitel Licensed IP Rights, the Vitel Owned IP Rights
and the Vitel Registered IP Rights.

 

“Vitel
Registered IP Rights” has the meaning set forth in Clause 3.1 (jj).

 

“Vitel
Shares” means 98 (ninety eight) shares of the fixed capital stock of Vitel, representing 98% of its outstanding capital
stock.

 

Clause
1.2 Interpretation of Defined Terms. The definitions set forth in the preceding Clause shall apply both in the singular
and plural form of such terms. When the context requires it, any pronoun shall include the corresponding male, female, and neutral
form. Unless the context requires otherwise, all references to clauses, paragraphs, subsections, items, or numbers of clauses
of this Agreement, and all references to schedules and exhibits, shall be deemed to be references to schedules and exhibits to
this Agreement, which are hereby incorporated by reference to form an integral part of this Agreement. Unless the context requires
otherwise, the words (a) “hereof”, “herein”, “hereunder”, “pursuant
hereto”, “below”, and words with similar meaning when used in this Agreement, shall be deemed to
refer to this Agreement in its entirety, and not to any specific clause, paragraph, subsection, item, or number of this Agreement;
(b) “include”, “includes”, and “including” shall be deemed followed by
the phrase, “but not limited to”, unless otherwise specified; and (c) “asset”, or “property”
shall be deemed to have the meaning and effect, and to refer to, each and every one of the assets and property, whether tangible
or intangible, including cash, shares, or interests, representing the capital stock of any company or Person, securities, income,
lease and contractual rights. Likewise, references to (i) any agreement, contract, document, or instrument, includes the reference
to such agreement, contract, document, or instrument, as amended, whether in whole or in part, supplemented, or otherwise altered
from time to time, and (ii) any law, rule, or regulation, includes the amendments thereto from time to time, or any law, rule,
or regulation that replaces them.

 

    	 	5	 

    	 		 

    

 

CLAUSE
II: CONTRIBUTION OF ASSETS; CONDITIONS TO CONTRIBUTION

 

Clause
2.1 Contribution. As per the terms of the Trust Agreement, the parties hereby acknowledge their contribution, assignment,
transfer, conveyance and delivery to the Trustee, free and clear of any liens or encumbrances, the following assets:

 

(a)
MCO and CAV transfer the Vitel Shares to the Trustee, and

 

(b)
OBMP transfers the OBMP Shares to the Trustee.

 

The
Trustee, as provided in the Trust Agreement, accepted and acquired from each party, all the right, title and interest in the Vitel
Shares and the OBMP Shares as of this date from each party. As per the terms of the Trust Agreement, the Trustee has acknowledged
the receipt of such assets, and as of the date hereof the Vitel Shares and the OBMP Shares shall form part of the Trust Property,
solely in furtherance of the Trust Purposes (as such terms are defined in the Trust Agreement).

 

Clause
2.2 Conditions to the Transaction. The obligations of the parties hereto, as well as the obligations of the parties to
the Shareholders’ Agreement to consummate the transactions contemplated by this Agreement and the Related Agreements (collectively,
the “Transactions”) at a closing to be held on the date hereof (the “Closing”) is subject
to the fulfillment of each of the following conditions: (i) as applicable, MCO and CAV will have obtained and delivered to OBMP
customary payoff letters and lien release documentation reasonably satisfactory to OBMP and their counsel relating to the repayment
of all debt of Vitel, including the termination of all liens on any assets of Vitel securing any such debt; (ii) MCO and CAV will
have forgiven all stockholder loans and related party debt to Vitel and its shareholders and their Affiliates on such terms that
are consistent with the provisions hereof, and provided to OBMP and Vitel (as applicable) releases in respect of any claims by
MCO and CAV against Vitel or OBMP relating to such loans; (iii) MCO and CAV will have obtained and delivered to OBMP the resignations
of each of the directors and officers of Vitel including MCO and CAV; (iv) Vitel will have an amount of working capital of $10,000.00
(ten thousand Dollars 00/100) as of the consummation of the Transactions; (v) each of Vitel and OBMP shall have a total indebtedness
in their balance sheet as of the date hereof in an amount of no greater than $450,000.00 (four hundred and fifty thousand Dollars
00/100) as set forth in the schedules of assets and liabilities of Vitel and the financial statements of OBMP, attached hereto
as Schedule 3.1(k) and Schedule 3.2(l), respectively; (vi) each of MCO and CAV shall have entered into employment
agreements with Vitel in form and substance satisfactory to OBMP; (vii) Vitel and OBMP shall each have received all necessary
governmental, board of directors and third-party approvals and consents to the Transactions; (viii) Vitel Asesores, S.C. shall
each have transferred all intellectual property in its name to Vitel; and (ix) MCO and CAV shall each have transferred one (1)
share of the fixed capital stock of Vitel representing 2% of its outstanding capital stock to OBMP. Promptly following the Closing,
OBMP shall direct the Trustee to sign the written consents necessary to amend OBMP’s charter and bylaws substantially in
the form of the documents attached to the Shareholders’ Agreement as Exhibit E and to elect MCO, CAV, Jonathan F.
Head and Andrew A. Kucharchuk as directors of Vitel and such directors to elect MCO, CAV, Jonathan F. Head and Andrew A. Kucharchuk
as officers of Vitel; and Vitel Asesores, S.C. shall have changed its name to a name not containing the word “Vitel”.

 

    	 	6	 

    	 		 

    

 

CLAUSE
III: REPRESENTATIONS AND WARRANTIES

 

Clause
3.1 Representations and Warranties of MCO and CAV. Except as set forth in the Schedules prepared by MCO and CAV and attached
hereto, each of MCO and CAV hereby represents and warrants, individually with respect to themselves, and jointly and severally
with respect to Vitel, that all statements contained in this Clause 3.1 are true, complete and correct with respect to
themselves as of the date of this Agreement. Moreover, MCO and CAV hereby represent that there has been no omission of information
of relevant aspects that would adversely affect the transaction between the parties of that if known by OBMP, would have had as
a reasonable result that OBMP would have decided not to enter into this Agreement:

 

(a)
Each is an individual, resident of Mexico, and Vitel is a variable stock corporation, duly organized and validly existing
under the laws of Mexico;

 

(b)
Each has full legal capacity and all requisite power and authority to enter into and comply with their obligations under this
Agreement pursuant to its terms;

 

(c)
Entering into and performing under this Agreement does not entail a violation or breach of (i) any agreement, contract,
license, resolution or order to which MCO, CAV or Vitel is a party (as applicable), or to which any of their assets is
subject; or (ii) any law, regulation, circular letter, order, decree from any Governmental Authority, its corporate bylaws or
any of its governing documents, applicable to each of MCO, CAV or Vitel (as applicable);

 

(d)
Each is the sole and exclusive owner of 49 shares (together, a total of 98 shares of the fixed capital stock of Vitel) which
together represent 98% of the outstanding capital stock of Vitel, which have been duly authorized, validly issued, fully paid
and non-assessable and having no connection to illegal activities, and are free from all liens, conditions, limitations or
restrictions on ownership, or any option or preferential right of any kind, except for the restrictions set forth in the
bylaws of Vitel and in the LGSM (as such term is defined below), which have been obtained from legal sources, as a result of
activities performed within the framework of the law, and that there is no connection whatsoever to illegal
activities;

 

(e)
Each of MCO and CAV shall transfer to the Trustee, as provided herein and for the Trust Purposes, ownership of and title over
his portion of the Vitel Shares;

 

(f)
The 49 shares of Vitel (together, a total of 98 shares of the fixed capital stock of Vitel) that each currently owns are not
subject to any contract, agreement, or any other document that pursuant to its terms (i) creates a call option or purchase
right, or any other right to acquire such shares, in favor of a third party; or (ii) restricts, in any way, any assignment,
transfer, or pledge, except for the restrictions set forth in the bylaws of Vitel and in the LGSM;

 

(g)
Except for the authorizations that, as applicable, have been obtained and are in full force and effect, no authorization or
approval whatsoever is required to enter into this Agreement, or to comply with or perform the obligations assumed by each of
MCO and CAV in terms of this Agreement, which are legal, valid, binding, and enforceable against him pursuant to their
respective terms;

 

    	 	7	 

    	 		 

    

 

(h)
As of this date there is no, and to the best of their knowledge there is no risk that any, action, complaint, claim, legal
requirement, or proceeding will be filed before any court, governmental agency, arbitrator, or judicial body with regard to
him or his property or Vitel or the property of Vitel (i) that affects the legality, validity, or enforceability of this
Agreement, (ii) the legal title over the Vitel Shares that each of MCO and CAV owns, or the transfer of the Vitel Shares to
the Trustee in accordance with the terms of the Trust Agreement, (iii) that prevents the consummation of any of the
transactions contemplated herein, or (iv) that may affect the value of OBMP’s investment in the Vitel
Shares;

 

(i)
Except as provided in Schedule 3.1 (i) hereof, there is no action, proceeding, arbitration, investigation or audit,
whether civil, criminal, administrative or judicial action pending or, to MCO and CAV’s knowledge, threatened, against
or involving MCO and CAV or Vitel as of the date of this Agreement. There are no judgments, rulings, assessments or
injunctions currently outstanding against Vitel;

 

(j)
Except as provided in Schedule 3.1 (j) hereof, Vitel does not own, directly or indirectly, any equity interest or
ownership stake in any Person, and has no commitment to contribute to the capital of, make loans to, or share in the losses
of, any Person;

 

(k)
True and complete copies of a list of the assets and liabilities of Vitel as of February 28, 2017 and as are set forth in Schedule
3.1 (k) hereto. Such list has been prepared from, are in accordance with and accurately reflect, the books and records
of Vitel, have been prepared in accordance with applicable law and IFRS and fairly present the changes in income,
stockholders’ equity and financial position of Vitel, as of the times and for the periods referred to therein and
properly reflect the financial position and results of operation of Vitel. Vitel maintains a standard system of accounting
established and administered in accordance with IFRS. There has been no material adverse change in the business, results of
operations, condition (financial or otherwise) or prospects of Vitel since February 28, 2017;

 

(l)
Vitel does not have any undisclosed liabilities, and (i) as of the date hereof, Vitel has an amount of working capital of
$10,000.00 (ten thousand Dollars 00/100); (ii) as of February 28, 2017 has a total indebtedness in its balance sheet in an
amount of no greater than $450,000.00 (four hundred and fifty thousand Dollars 00/100), as evidenced in Schedule
3.1(k) (exclusive of Vitel’s related party debt, as discussed in Clause 2.2 hereof); and (iii) after February 28,
2017 has incurred debt only in the normal course of Vitel’s business operations, with the understanding that no other
debts have been incurred as of the date hereof that would have a Material Adverse Effect on Vitel;

 

(m)
Except for the execution and delivery of this Agreement or as set forth in Schedule 3.1 (m), Vitel has conducted the
Vitel Business only in the ordinary course, and there has not been a Material Adverse Effect in Vitel;

 

(n)
Set forth on Schedule 3.1 (n) is a true, correct and complete list of all real property owned or leased by Vitel and
all real property leases, surveys, encumbrances, and material documents relating to such real property. Vitel has good and
marketable title to its respective estate in the owned real property. To MCO and CAV’s knowledge, there is no actual or
proposed condemnation, requisition or taking by any Governmental Authority of any portion of the real property or any
existing or proposed plan to modify or realign any street or highway abutting the real property. Vitel does not have any
right, title or interest in any real property other than the real property listed in Schedule 3.1 (n);

 

    	 	8	 

    	 		 

    

 

(o)
Vitel has good title to all of the tangible personal property reflected in the financial statements, free and clear of all
encumbrances. All facilities, machinery, equipment, fixtures, vehicles and other properties owned, leased or used by Vitel
are in good operating condition and repair (reasonable wear and tear excepted) and are reasonably fit and usable for the
purposes for which they are being used;

 

(p)
The current use of the real property is a lawful use and Vitel holds the necessary consents governing that use. To MCO and
CAV’s knowledge, such real property is not in violation of any applicable laws or third party rights;

 

(q) Schedule
3.1 (q) hereto sets forth a true, complete and correct list of every Material Contract to which the Vitel is a
party;

 

(r)
Except as set forth in Schedule 3.1 (r), (i) there is not and, to MCO and CAV’s knowledge, there has not been
any claim nor has it been alleged by any Person, with respect to any Material Contract, any existing or uncured breach or
event that, with notice or lapse of time or both, would constitute a breach on the part of Vitel, or, to MCO and CAV’s
knowledge, on the part of any other party thereto, and to MCO and CAV’s knowledge, none of the foregoing has been
threatened in writing; (ii) no consent from, or notice to, any governmental entity or other Person is required in order to
maintain in full force and effect any of Vitel’s contracts following the consummation of this Agreement (other than
such consents that have been obtained and such notices that have been duly given); and (iii) each of Vitel’s contracts
is in full force and effect and is valid and enforceable in accordance with its terms against the other parties thereto and,
to MCO and CAV’s knowledge, to other parties thereto;

 

(s)
There exist no contracts where the shareholders of Vitel (or one of its Affiliates other than Vitel) are a party by which
Vitel receives any rights or benefits, including supply contracts;

 

(t) Schedule
3.1 (t) includes a list of all policies of fire and casualty, liability and other forms of insurance maintained by or on
behalf of Vitel, along with the name of the holder of each such policy, and the amount of coverage and of any deductible
under each such policy. Each policy listed on Schedule 3.1 (t) is in full force and effect. No notice of cancellation
or nonrenewal with respect to, or disallowance of any claim under, or increase of the premium for any such insurance policy
listed on Schedule 3.1 (t) has been received by MCO or CAV, or to their knowledge, by Vitel. There is no default with
respect to any provision contained in any such insurance policy and there has not been any failure to give any notice or
present any claim under any such insurance policy in a timely fashion or in the manner or detail required by any such
insurance policy that would have a Material Adverse Effect on the ability of Vitel to enjoy the benefits of any such
insurance policy;

 

    	 	9	 

    	 		 

    

 

(u)
To MCO and CAV’s knowledge, Vitel has complied (except for such past noncompliance which has been fully resolved,
including payment of all fines, penalties or other sanctions) and is in compliance, with all applicable environmental laws,
including all consents issued pursuant to applicable environmental laws;

 

(v)
Neither MCO and CAV nor Vitel have received any written notice from any governmental entity or third party alleging that
Vitel is not in compliance with, or has or may have any liability or investigatory, corrective or remedial obligation under,
any environmental law the matter underlying which has not been fully resolved, including payment of all fines, penalties, or
other sanctions;

 

(w) Schedule
3.1 (w) sets forth a true, correct and complete list of all valid, subsisting and in good standing governmental permits
with respect to: (a) the ownership or use of Vitel’s properties and/or; (b) the operation of the Vitel Business, in
either case that are held by or for the benefit of Vitel (the “Vitel Governmental Permits”). Except for
the Vitel Governmental Permits, there are no other governmental permits necessary for: (a) the ownership or use of
Vitel’s properties; or (b) the operation of the Vitel Business. The execution of this Agreement and the obligations
contemplated herein shall not cause a default or breach of or result in the revocation or termination of any Vitel
Governmental Permits;

 

(x)
Vitel has complied and is in compliance, in each case in all respects, with all applicable laws;

 

(y)
All of the employee benefit plans of Vitel are in compliance in all respects with applicable law. Schedule 3.1 (y)
hereto contains a true and complete list of all employee benefit plans, which are available to an employee, officer or
director of Vitel due to their employment with Vitel;

 

(z)
There is no pending and there has not been any labor strike, dispute, slowdown, stoppage or lockout, with respect to Vitel,
and to MCO and CAV’s knowledge, no such action is threatened against Vitel, in each case, other than routine individual
grievances which are not Material to the Vitel Business, financial condition or results of operations of Vitel;

 

(aa)
Vitel is not a party to or bound by any collective bargaining contract or similar contract with any labor organization
applicable to employees of Vitel;

 

(bb)
No labor union is certified by a relevant labor relation’s authority, to the extent applicable, as bargaining agent for
any of the employees of Vitel and no union organizing or decertification activities are underway or, to MCO and CAV’s
knowledge, threatened;

 

(cc)
All payments, premiums, contributions, reports, returns and similar documents required to be made by any applicable law, have
been timely made to the appropriate payee. The consummation of obligations included herein will not result in the creation or
acceleration of any benefit or payment to an employee, officer or director of Vitel;

 

    	 	10	 

    	 		 

    

 

(dd)All
tax returns required to be filed by or with respect to Vitel in any jurisdiction to which it is subject, have been timely filed
and all taxes have been paid, including, but not limited to, the submission of tax returns and notices, payment of taxes and other
contributions, fines and surcharges, fees of the Mexican Social Security Institute (Instituto Mexicano del Seguro Social),
the National Workers Housing Fund Institute (Instituto Nacional del Fondo para la Vivienda de los Trabajadores) and the
Pension System (Sistema de Ahorro para el Retiro). All such tax returns are true, correct, complete, and set forth all
items required by applicable tax laws. Vitel has paid in full or set up an adequate reserve on the financial statements attached
to Schedule 3.1 (k) in respect of all taxes for the periods covered by such tax returns, and there are no outstanding governmental
tax encumbrances on any assets of Vitel. No tax examination or audit of Vitel is currently in progress or has been conducted since
the date of Vitel’s formation. Neither MCO or CAV, nor Vitel, have applied for and/or received a ruling from any tax authority
regarding a past or prospective transaction of Vitel that affects or may affect the tax liability of Vitel after date hereof;

 

(ee)Vitel
is not a party to a tax sharing agreement or similar contract, nor is it included in a consolidated tax return of another Person;

 

(ff)Vitel
is the sole and exclusive owner, or has the valid right or license to use, and, to the extent that it does any of the following,
to develop, make, have made, offer for sale, sell, import, copy, modify, create derivative works of, distribute, license, and
dispose of all intellectual property relating to, used in, or held for the Vitel Business or by Vitel (such intellectual property
being hereinafter collectively referred to as the “Vitel IP Rights”). Other than the Vitel IP Rights, neither
Vitel, nor MCO or CAV hold or own any other intellectual property of any kind, including any intellectual property that is similar
to the Vitel IP Rights. The Vitel IP Rights are sufficient for the conduct of the Vitel Business and Vitel has not transferred,
assigned, exclusively licensed or otherwise conveyed to any Affiliate or third party any of the Vitel IP Rights necessary for
the conduction of the Vitel Business. As used in this Agreement, “Vitel Owned IP Rights” means Vitel IP Rights
that are or are purportedly owned by Vitel; and “Vitel Licensed IP Rights” means Vitel IP Rights that are not
Vitel Owned IP Rights;

 

(gg)Neither
the execution, delivery and performance of this Agreement nor the consummation of the transaction between the parties as provided
herein will: (i) constitute a breach of or default under any instrument, license or other contract governing any Vitel IP Right;
(ii) cause the forfeiture or termination of, or give rise to a right of forfeiture or termination of, any Vitel IP Right; or (iii)
impair the right of Vitel to use, develop, make, have made, offer for sale, sell, import, copy, modify, create derivative works
of, distribute, license, or dispose of any Vitel IP Right or portion thereof;

 

(hh)Except
as set forth in Schedule 3.1 (hh), the operation of the Vitel Business has not infringed or misappropriated, or is infringing
or misappropriating, any intellectual property of any other party. There is no pending, or to the knowledge of MCO or CAV, threatened,
claim or litigation contesting the validity, ownership or right of Vitel to exercise any Vitel IP Right, nor, to the knowledge
of MCO or CAV, is there any legitimate basis for any such claim;

 

(ii)
Vitel has secured valid written assignments from all of Vitel’s current and former founders, interest holders,
officers, consultants, independent contractors and employees who were involved in, or who contributed to, the creation or
development of any Vitel Owned IP Rights. No current or former founder, interest holder, employee, officer, manager,
director, consultant or independent contractor of Vitel has any right, license, claim or interest whatsoever in or with
respect to any Vitel Owned IP Rights;

 

    	 	11	 

    	 		 

    

 

 

(jj)Schedule
3.1 (jj) of this Agreement contains a true and complete list of (1) Vitel Owned IP Rights (including all registrations of
any patents, copyrights, mask works, trademarks, service marks, and internet domain names, and all applications therefor), (2)
Vitel Licensed IP Rights, (3) all applications, registrations, filings and other formal written governmental actions made or taken
pursuant to applicable law by Vitel to secure, perfect or protect its interest in Vitel IP Rights and (4) all proceedings or actions
before any governmental authority, including the Instituto Mexicano de la Propiedad Industrial or equivalent authority
anywhere else in the world) related to any of Vitel IP Rights (collectively, the “Vitel Registered IP Rights”).
Except as set forth on Schedule 3.1 (hh), all Vitel Registered Owned IP Rights held by Vitel are valid, enforceable and
subsisting, and Vitel is the owner thereof. Except as set forth on Schedule 3.1 (jj), Vitel exclusively owns all trademarks
and trade names used in connection with the operation or conduct of the Vitel Business, including the sale, licensing, distribution
or provision of any Vitel products or services;

 

(kk)Except
as set forth on Schedule 3.1 (kk), there are no royalties, honoraria, fees or other payments payable by Vitel to any third
Person (other than salaries payable to employees and independent contractors not contingent on or related to use of their work
product) as a result of the use, license-in, manufacture, sale, offering for sale, copying, distribution, or disposition of any
Vitel Owned IP Rights by Vitel and none shall become payable as a result of the consummation of the transaction between the parties
as provided herein;

 

(ll)Neither
MCO or CAV, nor Vitel, or any Person acting in their behalf, has entered into any contract entitling any Person to any brokers’
or finder’s fee or any other commission or similar fee in connection with the execution and delivery of this Agreement;

 

(mm)All
receivables and trade accounts payable of Vitel are bona fide transactions in the ordinary course of business and valued in accordance
with IFRS. No receivable of Vitel is subject to any claim of reduction, customer credit balance, set-off, prepayment, counterclaim,
billing adjustment, recoupment or other claim for credit, allowances, adjustments, or subject to bankruptcy or similar proceedings;

 

(nn)All
inventory of Vitel consists of a quantity and quality usable and salable in the ordinary course of business, is not obsolete,
defective, damaged or slow moving (subject to reserves therefore reflected in the financial statements), is merchantable, fit
for its intended use and is valued in accordance with IFRS. No inventory of Vitel is subject to any consignment, bailment, and
warehousing or similar contract;

 

(oo)
Except as set forth on Schedule 3.1 (oo), Vitel owns or leases all the properties used in the Vitel
Business;

 

    	 	12	 

    	 		 

    

 

(pp)Except
as otherwise disclosed on Schedule 3.1 (pp) there are no liabilities or contracts between: (i) Vitel, on the one hand,
and (ii) MCO or CAV (or one of their affiliates) or any Person who currently is serving, or has within the past twenty-four months
served, as an officer, director, or equity holder of Vitel (or one of their Affiliates), on the other hand. Neither MCO or CAV,
nor any of their Affiliates has any interest in any properties used by Vitel;

 

(qq)Set
forth in Schedule 3.1(qq) are true and complete English translations of the bylaws of Vitel, which constitute all of its
governing documents;

 

(rr)Each
of MCO and CAV is an “accredited investor” as defined in Rule 501(a) under the Securities Act. Each of MCO and CAV
agrees to furnish any additional information requested by OBMP or any of its Affiliates to assure compliance with applicable U.S.
federal and state securities laws in connection with the acquisition of the OBMP Shares;

 

(ss)Each
of MCO and CAV is indirectly acquiring the OBMP Shares solely for their own beneficial account, for investment purposes, and not
with a view to, or for resale in connection with, any distribution of the OBMP Shares. Each of MCO and CAV understands that the
OBMP Shares have not been registered under the Securities Act or any state securities laws by reason of specific exemptions under
the provisions thereof which depend in part upon the investment intent of MCO and CAV and of the other representations made by
MCO and CAVO in this Agreement and the Related Agreements. MCO and CAV understand that OBMP is relying upon the representations
and agreements contained in this Agreement (and any supplemental information) for the purpose of determining whether the issuance
of the OBMP Shares pursuant to the Related Agreements meets the requirements for such exemptions;

 

(tt)Each
of MCO and CAV agrees: (A) that they will not sell, assign, pledge, give, transfer or otherwise dispose of the OBMP Shares or
any interest therein, or make any offer or attempt to do any of the foregoing, except pursuant to a registration of the OBMP Shares
under the Securities Act and all applicable state securities laws, or in a transaction which is exempt from the registration provisions
of the Securities Act and all applicable state securities laws; (B) that the certificates representing the OBMP Shares will bear
a legend making reference to the foregoing restrictions as described in Section 4.02 of the Shareholders’ Agreement;
and (C) that OBMP and its Affiliates shall not be required to give effect to any purported transfer of such OBMP Shares except
upon compliance with the foregoing restrictions;

 

(uu)Each
of MCO and CAV acknowledges that neither OBMP nor any other person offered to sell, issue or transfer the OBMP Shares to it by
means of any form of general solicitation or advertising, including but not limited to: (A) any advertisement, article, notice
or other article, notice or other communication published in any newspaper, magazine or similar media or broadcast over television
or radio or (B) any seminar or meeting whose attendees were invited by any general solicitation or general advertising;

 

(vv)Except
for the representations and warranties expressly contained in this Agreement, neither MCO or CAV, nor any other Person acting
on behalf of MCO or CAV, makes any representation or warranty, express or implied;

 

    	 	13	 

    	 		 

    

 

 

Clause
3.2 Representations and Warranties of OBMP. Except as set forth in the Schedules prepared by OBMP and attached hereto,
OBMP hereby represents and warrants, through its legal representative, that all statements contained in this Clause 3.2
are true, complete and correct as of the date of this Agreement. Moreover, OBMP hereby represents that there has been no omission
of information of relevant aspects that would adversely affect the transaction between the parties of that if known by MCO or
CAV, would have had as a reasonable result that MCO and CAV would have decided not to enter into this Agreement:

 

(a)
It is a corporation, duly organized and validly existing under the laws of the State of Nevada, USA;

 

(b)
It has full legal capacity and sufficient corporate authorizations to enter into and comply with its obligations under this
Agreement pursuant to its terms, and its representatives have all requisite power and authority to enter into this Agreement
on its behalf and perform its obligations hereunder;

 

(c)
Entering into and performing under this Agreement does not entail a violation or breach of (i) any provision of its articles
of incorporation, bylaws, or any of its governing documents; or (ii) any agreement, contract, license, resolution or order to
which it is a party, or to which OBMP, or any of its assets is subject; or (iii) any law, regulation, circular letter, order
or decree from any Governmental Authority applicable to OBMP;

 

(d)
OBMP has an authorized capital stock which consists of (i) 500,000,000 shares of common stock, par value $0.0001 per share,
and (ii) 20,000,000 shares of preferred stock, par value $0.0001 per share, and OBMP had 61,158,013 shares of common stock,
and 1,000,000 shares of Series A preferred stock, issued and outstanding as of February 20, 2017. Upon the Closing and the
consummation of the Transactions set forth herein and in the Related Agreements, (i) the Management Stockholders (as such
term is defined in the Shareholders’ Agreement) will collectively hold 21,926,078 shares of common stock, 250,000,000
shares of series A preferred stock, and 289,200,000 shares of series B preferred stock of OBMP, which represent at least 39%
(thirty nine per cent) but in no case greater that 40% (forty per cent) of the votes represented by the voting stock of OBMP;
(ii) the Vitel Stockholders (as such term is defined in the Shareholders’ Agreement) will collectively hold (indirectly
through the Trustee of the Trust Agreement) 61,158,013 shares of common stock, and 500,000,000 shares of series B preferred
stock of OMBP, which represent at least 39% (thirty nine per cent) but in no case greater than 40% (forty per cent) of the
votes represented by the voting stock of OBMP; and (iii) no other stockholder in OBMP will hold shares of OBMP which
represent more than 19% (nineteen per cent) of the votes represented by the voting stock of OBMP. Additionally, OBMP
represents that it has issued the OBMP Shares to the Trustee, to hold in its capacity as trustee of this Trust Agreement, for
the benefit of MCO and CAV, which shares are free from all liens, conditions, limitations or restrictions on ownership, or
any option or preferential right of any kind, and which have been duly authorized, validly issued, fully paid and
non-assessable, and that such issuance has no connection whatsoever to illegal activities;

 

(e)
It shall transfer to the Trustee, as provided herein and for the Trust Purposes, ownership of and title over the OBMP
Shares;

 

    	 	14	 

    	 		 

    

 

(f)
The OBMP Shares are not subject to any contract, agreement, or any other document that pursuant to its terms (i) creates a
call option or purchase right, or any other right to acquire such shares, in favor of a third party; or (ii) restricts, in
any way, any assignment, transfer, or pledge, except for the restrictions set forth in the Shareholders’
Agreement;

 

(g)
Except for the authorizations that, as applicable, have been obtained and are in full force and effect, no authorization or
approval whatsoever is required to enter into this Agreement, or to comply with or perform the obligations assumed by it in
terms of this Agreement, which are legal, valid, binding, and enforceable against OBMP pursuant to their respective
terms;

 

(h)
As of this date there is no, and to the best of its knowledge there is no risk that any, action, complaint, claim, legal
requirement, or proceeding will be filed before any court, governmental agency, arbitrator, or judicial body with regard to
OBMP or its property (i) that affects the legality, validity, or enforceability of this Agreement, (ii) the legal title over
the OBMP Shares or the transfer of the OBMP Shares to the Trustee in accordance with the terms of this Agreement, (iii) that
prevents the consummation of any of the transactions contemplated herein or (iv) that may affect the value of MCO and
CAV’s investment in the OBMP Shares;

 

(i)
Its representative has sufficient powers of attorney and authorities, and the corporate authorizations required to validly
enter into this Agreement on its behalf, and to validly bind OBMP under the terms hereof, and that such powers of attorney,
authorities, and corporate or other authorizations have not been revoked, amended, or limited in any way;

 

(j)
Except as provided in Schedule 3.2 (j) hereof, there is no action, proceeding, arbitration, investigation or audit,
whether civil, criminal, administrative or judicial action pending or, to OBMP’s knowledge, threatened, against or
involving OBMP as of the date of this Agreement. There are no judgments, rulings, assessments or injunctions currently
outstanding against OBMP;

 

(k)
Except as provided in Schedule 3.2 (k) hereof, OBMP does not own, directly or indirectly, any equity interest or
ownership stake in any Person, and has no commitment to contribute to the capital of, make loans to, or share in the losses
of, any Person;

 

(l)
True and complete copies of the financial statements of OBMP as of September 30, 2016 and as are set forth in Schedule 3.2
(l) hereto. The financial statements have been prepared from, are in accordance with and accurately reflect, the books
and records of OBMP, have been prepared in accordance with applicable law and U.S. GAAP, and fairly present the changes in
income, stockholders’ equity and financial position of OBMP, as of the times and for the periods referred to therein
and properly reflect the financial position and results of operation of OBMP. OBMP maintains a standard system of accounting
established and administered in accordance with U.S. GAAP. There has been no material adverse change in the business, results
of operations, condition (financial or otherwise) or prospects of OBMP since September 30, 2106;

 

    	 	15	 

    	 		 

    

 

(m)
OBMP does not have any undisclosed liabilities, and (i) as of September 30, 2016, OBMP had a total indebtedness (consisting
of loans payable, convertible notes and line of credit drawings) in its balance sheet in an amount of no greater than
$450,000.00 (four hundred and fifty thousand Dollars 00/100), as evidenced in Schedule 3.2(l); (ii) on November 2016
it obtained a financing which will be reported in its financial statements as of December 31st, 2016; and (iii)
after September 30, 2016 has incurred debt only in the normal course of OBMP’s business operations, with the
understanding that no other debts have been incurred as of the date hereof that would have a Material Adverse Effect in
OBMP;

 

(n)
Except for the execution and delivery of this Agreement or as set forth in Schedule 3.2 (n), OBMP has conducted the
OBMP Business only in the ordinary course, and there has not been a Material Adverse Effect in OBMP;

 

(o)
Set forth on Schedule 3.2 (o) is a true, correct and complete list of all real property owned or leased by OBMP and
all real property leases, surveys, encumbrances, and material documents relating to such real property. OBMP has good and
marketable title to its respective estate in the owned real property. To OBMP’s knowledge, there is no actual or
proposed condemnation, requisition or taking by any Governmental Authority of any portion of the real property or any
existing or proposed plan to modify or realign any street or highway abutting the real property. OBMP does not have any
right, title or interest in any real property other than the real property listed in Schedule 3.2 (o);

 

(p)
OBMP has good title to all of the tangible personal property reflected in the financial statements, free and clear of all
encumbrances. All facilities, machinery, equipment, fixtures, vehicles and other properties owned, leased or used by OBMP are
in good operating condition and repair (reasonable wear and tear excepted) and are reasonably fit and usable for the purposes
for which they are being used;

 

(q)
The current use of the real property is a lawful use and OBMP holds the necessary consents governing that use. To
OBMP’s knowledge, such real property is not in violation of any applicable laws or third party rights;

 

(r) Schedule
3.2 (r) hereto sets forth a true, complete and correct list of every Material Contract (i) to which OBMP is a party; and
(ii) which has not been filed as an exhibit to a periodic report filed by OMBP with the Securities and Exchange Commission in
the United States of America;

 

(s)
Except as set forth in Schedule 3.2 (s), (i) there is not and, to OBMP’s knowledge, there has not been any claim
nor has it been alleged by any Person, with respect to any Material Contract, any existing or uncured breach or event that,
with notice or lapse of time or both, would constitute a breach on the part of OBMP, or, to OBMP’s knowledge, on the
part of any other party thereto, and to OBMP’s knowledge, none of the foregoing has been threatened in writing; (ii) no
consent from, or notice to, any governmental entity or other Person is required in order to maintain in full force and effect
any of OBMP’s contracts following the consummation of this Agreement (other than such consents that have been obtained
and such notices that have been duly given); and (iii) each of OBMP’s contracts is in full force and effect and is
valid and enforceable in accordance with its terms against the other parties thereto and, to OBMP’s knowledge, to other
parties thereto;

 

    	 	16	 

    	 		 

    

 

(t)
Except as set forth in Schedule 3.2(t), there exist no contracts where the shareholders of OBMP (or one of its
Affiliates other than OBMP) are a party by which OBMP receives any rights or benefits, including supply contracts;

 

(u) Schedule
3.2 (u) includes a list of all policies of fire and casualty, liability and other forms of insurance maintained by or on
behalf of OBMP, along with the name of the holder of each such policy, and the amount of coverage and of any deductible under
each such policy. Each policy listed on Schedule 3.2 (u) is in full force and effect. No notice of cancellation or
nonrenewal with respect to, or disallowance of any claim under, or increase of the premium for any such insurance policy
listed on Schedule 3.2 (u) has been received by OBMP. There is no default with respect to any provision contained in
any such insurance policy and there has not been any failure to give any notice or present any claim under any such insurance
policy in a timely fashion or in the manner or detail required by any such insurance policy that would have a Material
Adverse Effect on the ability of OBMP to enjoy the benefits of any such insurance policy;

 

(v)
OBMP has complied (except for such past noncompliance which has been fully resolved, including payment of all fines,
penalties or other sanctions) and is in compliance, with all applicable environmental laws, including all consents issued
pursuant to applicable environmental laws;

 

(w)
OBMP has not received any written notice from any Governmental Authority or third party alleging that OBMP is not in
compliance with, or has or may have any liability or investigatory, corrective or remedial obligation under, any
environmental law the matter underlying which has not been fully resolved, including payment of all fines, penalties, or
other sanctions;

 

(x) Schedule
3.2 (x) sets forth a true, correct and complete list of all valid, subsisting and in good standing governmental permits
with respect to: (a) the ownership or use of OBMP’s properties and/or; (b) the operation of the OBMP Business, in
either case that are held by or for the benefit of OBMP (the “OBMP Governmental Permits”). Except for the
OBMP Governmental Permits, there are no other governmental permits necessary for: (a) the ownership or use of OBMP’s
properties or; (b) the operation of the OBMP Business. The execution of this Agreement and the obligations contemplated
herein shall not cause a default or breach of or result in the revocation or termination of any OBMP Governmental
Permits;

 

(y)
OBMP has complied and is in compliance, in each case in all respects, with all applicable laws;

 

(z)
All of the employee benefit plans of OBMP are in compliance in all respects with applicable law. Schedule 3.2 (z)
hereto contains a true and complete list of all employee benefit plans, which are available to an employee, officer or
director of OBMP due to their employment with OBMP;

 

    	 	17	 

    	 		 

    

 

(aa)There
is no pending and there has not been any labor strike, dispute, slowdown, stoppage or lockout, with respect to OBMP, and to OBMP’s
knowledge, no such action is threatened against OBMP, in each case, other than routine individual grievances which are not Material
to the OBMP Business, financial condition or results of operations of OBMP;

 

(bb)OBMP
is not a party to or bound by any collective bargaining contract or similar contract with any labor organization applicable to
employees of OBMP;

 

(cc)No
labor union is certified by a relevant labor relation’s authority, to the extent applicable, as bargaining agent for any
of the employees of OBMP and no union organizing or decertification activities are underway or, to OBMP’s knowledge, threatened;

 

(dd)All
payments, premiums, contributions, reports, returns and similar documents required to be made by any applicable law, have been
timely made to the appropriate payee. The consummation of obligations included herein will not result in the creation or acceleration
of any benefit or payment to an employee, officer or director of OBMP;

 

(ee)All
tax returns required to be filed by or with respect to OBMP in any jurisdiction to which it is subject, have been timely filed
and all taxes have been paid, including, but not limited to, the submission of tax returns and notices, payment of taxes and other
contributions, fines and surcharges. All such tax returns are true, correct, complete, and set forth all items required by applicable
tax laws. OBMP has paid in full or set up an adequate reserve on the financial statements attached to Schedule 3.2 (l)
in respect of all taxes for the periods covered by such tax returns, and there are no outstanding governmental tax encumbrances
on any assets of OBMP. No tax examination or audit of OBMP is currently in progress or has been conducted since the date of OBMP’s
formation. OBMP has not applied for and/or received a ruling from any tax authority regarding a past or prospective transaction
of OBMP that affects or may affect the tax liability of OBMP after date hereof;

 

(ff)OBMP
is not a party to a tax sharing agreement or similar contract, nor is it included in a consolidated tax return of another Person;

 

(gg)OBMP
is the sole and exclusive owner, or has the valid right or license to use, and, to the extent that it does any of the following,
to develop, make, have made, offer for sale, sell, import, copy, modify, create derivative works of, distribute, license, and
dispose of all intellectual property relating to, used in, or held for the OBMP Business or by OBMP, other than the intellectual
property that is owned by OBMP Mexico (such intellectual property being hereinafter collectively referred to as the “OBMP
IP Rights”). Other than the OBMP IP Rights, OBMP does not hold or own any other intellectual property of any kind, including
any intellectual property that is similar to the OBMP IP Rights. The OBMP IP Rights are sufficient for the conduct of the OBMP
Business and OBMP has not transferred, assigned, exclusively licensed or otherwise conveyed to any Affiliate or third party any
of the OBMP IP Rights necessary for the conduction of the OBMP Business. As used in this Agreement, “OBMP Owned IP Rights”
means OBMP IP Rights that are or are purportedly owned by OBMP; and “OBMP Licensed IP Rights” means OBMP IP
Rights that are not OBMP Owned IP Rights;

 

    	 	18	 

    	 		 

    

 

(hh)Neither
the execution, delivery and performance of this Agreement nor the consummation of the transaction between the parties as provided
herein will: (i) constitute a breach of or default under any instrument, license or other contract governing any OBMP IP Right;
(ii) cause the forfeiture or termination of, or give rise to a right of forfeiture or termination of, any OBMP IP Right; or (iii)
impair the right of OBMP to use, develop, make, have made, offer for sale, sell, import, copy, modify, create derivative works
of, distribute, license, or dispose of any OBMP IP Right or portion thereof;

 

(ii)
Except as set forth in Schedule 3.2 (ii), the operation of the OBMP Business has not infringed or misappropriated, or
is infringing or misappropriating, any intellectual property of any other party. There is no pending, or to the knowledge of
OBMP, threatened, claim or litigation contesting the validity, ownership or right of OBMP to exercise any OBMP IP Right, nor,
to the knowledge of OBMP, is there any legitimate basis for any such claim;

 

(jj)OBMP
has secured valid written assignments from all of OBMP’s current and former founders, interest holders, officers, consultants,
independent contractors and employees who were involved in, or who contributed to, the creation or development of any OBMP Owned
IP Rights. No current or former founder, interest holder, employee, officer, manager, director, consultant or independent contractor
of OBMP has any right, license, claim or interest whatsoever in or with respect to any OBMP Owned IP Rights;

 

(kk)Schedule
3.2 (kk) of this Agreement contains a true and complete list of (1) OBMP Owned IP Rights (including all registrations of any
patents, copyrights, mask works, trademarks, service marks, and internet domain names, and all applications therefor), (2) OBMP
Licensed IP Rights, (3) all applications, registrations, filings and other formal written governmental actions made or taken pursuant
to applicable law by OBMP to secure, perfect or protect its interest in OBMP IP Rights and (4) all proceedings or actions before
any governmental authority, including the Instituto Mexicano de la Propiedad Industrial or equivalent authority anywhere
else in the world) related to any of OBMP IP Rights (collectively, the “OBMP Registered IP Rights”). Except
as set forth on Schedule 3.2 (ii), all OBMP Registered Owned IP Rights held by OBMP are valid, enforceable and subsisting,
and OBMP is the owner thereof. Except as set forth on Schedule 3.2 (kk), OBMP exclusively owns all trademarks and trade
names used in connection with the operation or conduct of the OBMP Business, including the sale, licensing, distribution or provision
of any OBMP products or services;

 

(ll)Except
as set forth on Schedule 3.2 (ll), there are no royalties, honoraria, fees or other payments payable by OBMP to any third
Person (other than salaries payable to employees and independent contractors not contingent on or related to use of their work
product) as a result of the use, license-in, manufacture, sale, offering for sale, copying, distribution, or disposition of any
OBMP Owned IP Rights by OBMP and none shall become payable as a result of the consummation of the transaction between the parties
as provided herein;

 

(mm)Neither
OBMP, nor any Person acting in its behalf, has entered into any contract entitling any Person to any brokers’ or finder’s
fee or any other commission or similar fee in connection with the execution and delivery of this Agreement;

 

    	 	19	 

    	 		 

    

 

(nn)All
receivables and trade accounts payable of OBMP are bona fide transactions in the ordinary course of business and valued in accordance
with U.S. GAAP. No receivable of OBMP is subject to any claim of reduction, customer credit balance, set-off, prepayment, counterclaim,
billing adjustment, recoupment or other claim for credit, allowances, adjustments, or subject to bankruptcy or similar proceedings;

 

(oo)
All inventory of OBMP consists of a quantity and quality usable and salable in the ordinary course of business, is not
obsolete, defective, damaged or slow moving (subject to reserves therefore reflected in the financial statements), is
merchantable, fit for its intended use and is valued in accordance with IFRS. No inventory of OBMP is subject to any
consignment, bailment, and warehousing or similar contract;

 

(pp)Except
as set forth on Schedule 3.2 (pp), OBMP owns or leases all the properties used in the OBMP Business;

 

(qq)Except
as otherwise disclosed on Schedule 3.2 (qq) there are no liabilities or contracts between: (i) OBMP (or one of its affiliates),
on the one hand, and (ii) its current shareholders (or one of their Affiliates) or any Person who currently is serving, or has
within the past twenty-four months served, as an officer, director, or equity holder of OBMP (or one of their Affiliates), on
the other hand. Neither OBMP, nor any of its Affiliates has any interest in any properties used by OBMP;

 

(rr)Subject
to Section 3.04 of the Shareholders’ Agreement, all members of the Board of Directors of OBMP have the same approval rights,
in the understanding that the Vitel Designee (as such term is defined in the Shareholders’ Agreement) to the Board of OBMP
shall have the same approval rights as any other member of the Board of OBMP.

 

(ss)Except
for the representations and warranties expressly contained in this Agreement, neither OBMP, nor any other Person acting on behalf
of OBMP, makes any representation or warranty, express or implied.

 

CLAUSE
IV: INDEMNIFICATION

 

Clause
4.1 Indemnification by MCO and CAV.

 

(a)
Subject to the limitations set forth in this Clause IV, from and after the date hereof, MCO and CAV jointly and
severally (in accordance with their respective pro rata percentage of the OBMP Shares they both hold) shall indemnify and
hold harmless, and agree to pay and/or reimburse OBMP and its Affiliates and the representatives, Affiliates, successors and
assigns of each of the foregoing Persons (each, an “OBMP Indemnified Person”), from, against and in
respect of any and all actions, liabilities, governmental orders, encumbrances, losses, damages, bonds, dues, assessments,
fines, penalties, taxes, fees, costs (including reasonable costs of investigation, defense and enforcement of this
Agreement), expenses or amounts paid in settlement (including reasonable attorneys’ and experts’ fees and
expenses), whether or not involving a Third Party Claim (collectively, “Losses”), incurred or suffered by
the OBMP Indemnified Person(s) or any of them, as a result of, arising out of or relating to, directly or
indirectly:

 

    	 	20	 

    	 		 

    

 

(i)
any fraud or intentional misrepresentation on the part of Vitel (or any Affiliate (other than a MCO or CAV) or representative
thereof) or any breach of, or inaccuracy in, any representation, warranty or statement made by or on behalf of Vitel in this
Agreement or in any schedule or certificate delivered by or on behalf of Vitel pursuant to this Agreement;

 

(ii)
any breach or violation of any covenant or agreement of Vitel to the extent required to be performed or complied with by
Vitel at or prior to the date hereof in or pursuant to this Agreement;

 

(iii)
any fraud or international misrepresentation on the part of any MCO or CAV (or any Affiliate (other than Vitel) or
representative thereof) or any breach of, or inaccuracy in, any representation, warranty or statement made by or on behalf of
MCO or CAV in this Agreement or in any schedule or certificate delivered by or on behalf of MCO or CAV pursuant to this
Agreement;

 

(iv)
any breach or violation of any covenant or agreement of MCO or CAV (including under this Clause IV) in or pursuant to
this Agreement;

 

(v)
any liability or cost arising out of the manner in which Vitel compensates its employees and other persons who work or have
worked for Vitel, which have originated at any point prior to and including the date of this Agreement; or

 

(vi)
past taxes (including interest and penalties) imposed in respect of the income, business, property or operations of Vitel, or
for which MCO or CAV may otherwise be liable for the period up to and including the date of this Agreement.

 

(b) Monetary
Limitations. MCO and CAV will have no obligation to indemnify any OBMP Indemnified Person pursuant to Clauses
4.1(a)(i) and 4.1(a)(iii) hereof, unless and until the aggregate amount of all such Losses incurred or suffered by
the OBMP Indemnified Persons exceeds $50,000.00 (fifty thousand Dollars 00/100) (at which point MCO and CAV will indemnify
the OBMP Indemnified Persons for all such Losses in excess of $50,000.00), and the aggregate liability of MCO and CAV in
respect of claims for indemnification pursuant to Clauses 4.1(a)(i) through 4.1(a)(vi) will not exceed the
total value of the OBMP Shares as of the date hereof; provided, that the foregoing limitations will not apply to
claims based upon gross negligence, fraud or intentional misrepresentation.

 

Clause
4.2 Indemnification by OBMP.

 

(a) Indemnification.
Subject to the limitations set forth in this Clause IV, from and after the date hereof, OBMP shall indemnify and hold
harmless, and agree to pay and/or reimburse each of MCO and CAV and each of their respective Affiliates (other than OBMP and
Vitel), and the representatives, Affiliates, successors and assigns of each of the foregoing Persons (each, a “Vitel
Indemnified Person”), from, against and in respect of any and all Losses incurred or suffered by the Vitel
Indemnified Persons or any of them as a result of, arising out of or relating to, directly or indirectly:

 

    	 	21	 

    	 		 

    

 

(i)
any fraud or intentional misrepresentation on the part of OBMP (or any Affiliate (other than Vitel) or representative
therBeof) or any breach of, or inaccuracy in, any representation, warranty or statement made by or on behalf of OBMP in this
Agreement or in any schedule or certificate delivered by or on behalf of OBMP pursuant to this Agreement;

 

(ii)
any breach or violation of any covenant or agreement of OBMP to the extent required to be performed or complied with by OBMP
at or prior to the date hereof in or pursuant to this Agreement;

 

(iii)
any liability or cost arising out of the manner in which OBMP compensates its employees and other persons who work or have
worked for OBMP, which have originated at any point prior to and including the date of this Agreement; or

 

(iv)
past taxes (including interest and penalties) imposed in respect of the income, business, property or operations of OBMP, or
for which any OBMP stockholder may otherwise be liable for the period up to and including the date of this
Agreement.

 

(b) Monetary
Limitations. OBMP will have no obligation to indemnify any Vitel Indemnified Person pursuant to Clause 4.2(a)(i)
hereof, unless and until the aggregate amount of all such Losses incurred or suffered by the Vitel Indemnified Persons
exceeds $50,000.00 (fifty thousand Dollars 00/100) (at which point OBMP will indemnify the Vitel Indemnified Persons for all
such Losses in excess of $50,000) and OBMP’s aggregate liability in respect of claims for indemnification pursuant to Clauses
4.2(a)(i) through 4.2(a)(iv) will not exceed the total value of the OBMP Shares as of the date hereof; provided,
that the foregoing limitations will not apply to claims based upon gross negligence, fraud or intentional
misrepresentation.

 

Clause
4.3. Timing for Claims; Notice of Claims

 

(a) Timing
for Claims. No claim may be made or suit instituted seeking indemnification pursuant to Clause 4.1(a)(i), 4.1(a)(iii) or 4.2(a)(i)
and 4.2(a)(iii) for any breach of, or inaccuracy in, any representation, warranty or statement unless a written notice is
provided to the Indemnifying Party:

 

(i)
at any time, in the case of any breach of, or inaccuracy in, the Fundamental Representations;

 

(ii)
at any time, in the case of any claim or suit based upon fraud or intentional misrepresentation;

 

(iii)
at any time prior to the thirtieth (30th) day following the expiration of the applicable statute of limitations (taking into
account any tolling periods and other extensions) in the case of any breach of, or inaccuracy in, the Specified
Representations; and

 

    	 	22	 

    	 		 

    

 

(iv)
at any time prior to the twenty four (24) month anniversary of the date hereof (the “General Indemnity Survival
Period”), in the case of any breach of, or inaccuracy in, any other representation, warranty or statement in this
Agreement or in any schedule or certificate delivered pursuant to this Agreement.

 

Claims
for indemnification pursuant to any other provision of Clause 4.1(a) and 4.2(a) are not subject to the limitations
set forth in this Clause 4.3.

 

(b) Written
Notice of Indemnification Claims. In the event that any Indemnified Person wishes to make a claim for indemnification
under this Clause IV, the Indemnified Person shall give written notice of such claim to each Indemnifying Party within
the applicable time limitations contained in Clause 4.3(a). Any such notice shall describe the breach or inaccuracy
and other material facts and circumstances upon which such claim is based and the estimated amount of Losses involved, in
each case, in reasonable detail in light of the facts then known to the Indemnified Person; provided, that no defect
in the information contained in such notice from the Indemnified Person to any Indemnifying Party will relieve such
Indemnifying Party from any obligation under this Clause IV, except to the extent such failure to include information
actually and materially prejudices such Indemnifying Party.

 

Clause
4.4 Third Party Claims

 

(a) Notice
of Third Party Claims. Promptly after receipt by an Indemnified Person of written notice of the assertion of a claim by
any Person who is not a party to this Agreement (a “Third Party Claim”) that may give rise to an indemnity
claim against an Indemnifying Party under this Clause IV, the Indemnified Person shall give written notice thereof to
the Indemnifying Party; provided, that no delay on the part of the Indemnified Person in notifying the Indemnifying
Party will relieve the Indemnifying Party from any obligation under this Clause IV, except to the extent such delay
actually and materially prejudices the Indemnifying Party.

 

(b) Assumption
of Defense, etc. The Indemnifying Party will be entitled to participate in the defense of any Third Party Claim
that is the subject of a notice given by or on behalf of any Indemnified Person pursuant to Clause 4.4(a). In
addition, the Indemnifying Party will have the right to defend the Indemnified Person against the Third Party Claim with
counsel of its choice reasonably satisfactory to the Indemnified Person so long as (i) the Indemnifying Party gives written
notice that they or it will defend the Third Party Claim to the Indemnified Person within thirty (30) days after the
Indemnified Person has given notice of the Third Party Claim under Clause 4.4(a) stating that the Indemnifying Party
will, and thereby covenants to, indemnify, defend and hold harmless the Indemnified Person from and against the entirety of
any and all Losses the Indemnified Person may suffer resulting from, arising out of, relating to, in the nature of, or caused
by the Third Party Claim, (ii) the Indemnifying Party provides the Indemnified Person with evidence reasonably acceptable to
the Indemnified Person that the Indemnifying Party will have adequate financial resources to defend against the Third Party
Claim and fulfill its indemnification obligations hereunder, (iii) the Third Party Claim involves only money damages and does
not seek an injunction or other equitable relief against the Indemnified Person, (iv) the Indemnified Person has not been
advised by counsel that an actual or potential conflict exists between the Indemnified Person and the Indemnifying Party in
connection with the defense of the Third Party Claim, (v) the Third Party Claim does not relate to or otherwise arise in
connection with Taxes or any criminal or regulatory enforcement action, (vi) settlement of, an adverse judgment with respect
to, or conduct of the defense of the Third Party Claim by the Indemnifying Party is not, in the good faith judgment of the
Indemnified Person, likely to be adverse to the Indemnified Person’s reputation or continuing business interests
(including its relationships with current or potential customers, suppliers or other parties material to the conduct of its
business) and (vii) the Indemnifying Party conducts the defense of the Third Party Claim actively and diligently. The
Indemnified Person may retain separate co-counsel at its sole cost and expense and participate in the defense of the
Third Party Claim; provided, that the Indemnifying Party will pay the fees and expenses of separate counsel retained
by the Indemnified Person that are incurred prior to the Indemnifying Party’s assumption of control of the defense of
the Third Party Claim.

 

    	 	23	 

    	 		 

    

 

(c) Limitations
on Indemnifying Party Control. The Indemnifying Party will not consent to the entry of any judgment or enter into any
compromise or settlement with respect to the Third Party Claim without the prior written consent of the Indemnified Person
unless such judgment, compromise or settlement (i) provides for the payment by the Indemnifying Party of money as sole relief
for the claimant, (ii) results in the full and general release of all Indemnified Person from all liabilities arising or
relating to, or in connection with, the Third Party Claim and (iii) involves no finding or admission of any violation of
legal requirements or the rights of any Person.

 

(d) Indemnified
Person’s Control. If the Indemnifying Party does not deliver the notice contemplated by sub-section (i) of Clause
4.4(b), or the evidence contemplated by sub-section (ii) of Clause 4.4(b), within ninety (90) days after the
Indemnified Person has given notice of the Third Party Claim pursuant to Clause 4.4(a), or otherwise at any time fails
to conduct the defense of the Third Party Claim actively and diligently, the Indemnified Person may defend, and may consent
to the entry of any judgment or enter into any compromise or settlement with respect to, the Third Party Claim in any manner
it may deem appropriate (and the Indemnified Person need not consult with, or obtain any consent from, the Indemnifying Party
in connection therewith). If such notice and evidence is given on a timely basis and the Indemnifying Party conducts the
defense of the Third Party Claim actively and diligently but any of the other conditions in Clause 4.4(b) is or
becomes unsatisfied, the Indemnified Person may defend, and may consent to the entry of any judgment or enter into any
compromise or settlement with respect to, the Third Party Claim; provided, that the Indemnifying Party will not be
bound by the entry of any such judgment consented to, or any such compromise or settlement effected, without its prior
written consent (which consent will not be unreasonably withheld, conditioned or delayed). In the event that the Indemnified
Person conducts the defense of the Third Party Claim pursuant to this Clause 4.4(d), the Indemnifying Party will (i)
advance the Indemnified Person promptly and periodically for the costs of defending against the Third Party Claim (including
reasonable attorneys’ fees and expenses) and (ii) remain responsible for any and all other Losses that the Indemnified
Person may incur or suffer resulting from, arising out of, relating to, in the nature of or caused by the Third Party Claim
to the fullest extent provided in this Clause IV.

 

    	 	24	 

    	 		 

    

 

(e) Consent
to Jurisdiction Regarding Third Party Claim. OBMP and each of MCO and CAV, hereby consent to the non-exclusive
jurisdiction of any court in which any Third Party Claim may be brought against any Indemnified Person for purposes of any
claim which such Indemnified Person may have against any such Indemnifying Party pursuant to this Agreement in connection
with such Third Party Claim, and in furtherance thereof, the provisions of Clause 5.6 are incorporated herein by
reference, mutatis mutandis.

 

Clause
4.5 No Circular Recovery. Each of MCO and CAV hereby agrees that they will not make any claim for indemnification against
OBMP by reason of the fact that each was a controlling person, director, employee or representative of OBMP or Vitel or was serving
as such for another Person at the request of OBMP or Vitel (whether such claim is for Losses of any kind or otherwise and whether
such claim is pursuant to any legal requirement, organizational document, contractual obligation or otherwise) with respect to
any claim brought by an OBMP Indemnified Person against any of MCO or CAV under this Agreement or otherwise relating to this Agreement.
With respect to any claim brought by an OBMP Indemnified Person against MCO or CAV under this Agreement or otherwise relating
to this Agreement, each of MCO and CAV expressly waives any right of subrogation, contribution, advancement, indemnification or
other claim against any of OBMP or Vitel with respect to any amounts owed by MCO or CAV pursuant to this Clause IV or otherwise

 

Clause
4.6 Indemnity from Trust Shares.

 

(a)
For as long as there are OBMP Shares in the Trust maintained under the Trust Agreement, any and all amounts payable by MCO
and CAV as Indemnifying Party to an OBMP Indemnified Person will be paid in OBMP Shares first out of such Trust and based on
the Fair Market Value (as such term is defined in the Shareholders’ Agreement) of the OBMP Shares on the date of
payment, and thereafter, if and when such OBMP Shares are exhausted, by MCO and CAV as herein provided in cash in accordance
with payment instructions provided by OBMP. Subject to Clause 4.1(b), the existence of the OBMP Shares in the Trust
will not be deemed to limit the amount of any allowable claims by any OBMP Indemnified Person pursuant to this Agreement for
Losses in excess of the value of such OBMP Shares.

 

(b)
For as long as there are Vitel Shares in the Trust maintained under the Trust Agreement, any and all amounts payable by OBMP
as Indemnifying Party to a Vitel Indemnified Person will be paid in Vitel Shares first out of such Trust and based on the
Fair Market Value of the Vitel Shares on the date of payment, and thereafter, if and when such Vitel Shares are exhausted, by
OBMP as herein provided in cash in accordance with payment instructions provided by MCO and CAV. Subject to Clause
4.2(b), the existence of the Vitel Shares in the Trust will not be deemed to limit the amount of any allowable claims by
any Vitel Indemnified Person pursuant to this Agreement for Losses in excess of the value of such Vitel Shares.

 

Clause
4.7 Insurance Proceeds. Payments by an Indemnifying Party pursuant to Clause 4.1 or Clause 4.2 in respect
of any Losses shall be limited to the amount of any liability or damage that remains after deducting therefrom any insurance proceeds
and any indemnity, contribution or other similar payment actually received by the Indemnified Person in respect of any such claim,
in each case, in the year in which the applicable indemnified Losses are incurred.

 

    	 	25	 

    	 		 

    

 

Clause
4.8 Indemnification Exclusive Remedy. Except for claims based on fraud, from and after the date hereof, the right of each
party hereto to demand and receive indemnification payments pursuant to this Clause IV shall be the sole and exclusive
right and remedy exercisable by such party with respect to any matters relating to, or arising under, this Agreement.

 

Clause
4.9 Remedies Cumulative. The rights of each Indemnified Person under this Clause IV are cumulative, and each Indemnified
Person will have the right in any particular circumstance, in its sole discretion, to enforce any provision of this Clause
IV without regard to the availability of a remedy under any other provision of this Clause IV.

 

CLAUSE
V: GENERAL PROVISIONS

 

Clause
5.1 Confidentiality

 

(a)
The parties hereto agree that Confidential Information (as defined below) furnished and to be furnished to each was and shall
be made available in connection with their investment in OBMP and Vitel, and in furtherance of the purposes of this Agreement
and the Shareholders’ Agreement. Each party hereto acknowledges that the Confidential Information that each has
obtained or will obtain is the property of OBMP and Vitel, and each of their Subsidiaries. Each party hereto agrees that he
or she will not disclose any Confidential Information to any other Person, except that Confidential Information may be
disclosed: (i) to the extent required by applicable law, rule or regulation (including complying with any oral or written
questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar process to
which a party hereto is subject or as required to be disclosed by OBMP pursuant to federal securities laws in force in the
United States of America which are applicable to OBMP); provided that such party gives OBMP and/or Vitel (as applicable)
prompt notice of such requests other than disclosure requirements of the Securities and Exchange Commission of the United
States of America, to the extent practicable, so that OBMP and/or Vitel (as applicable) may seek an appropriate protective
order or similar relief (and the parties hereto shall cooperate with such efforts by OBMP and/or Vitel, and shall in any
event make only the minimum disclosure required by such law, rule or regulation, other than federal securities laws in force
in the United States of America which are applicable to OBMP, disclosure which OBMP may make in its reasonable discretion),
(ii) after the later of a period of five (5) years from and after the date of this Agreement and or (2) years following the
date on which a party hereto ceases to be a stockholder of OBMP, or (iii) if the prior written consent of OBMP and/or Vitel
(as applicable) shall have been obtained. For the purposes of clarity and the avoidance of doubt the parties hereto
acknowledge and agree that, following the consummation of the transactions contemplated by this Agreement, OBMP shall not be
required to seek the consent of MCO or CAV for the use of any of Vitel’s Confidential Information which shall become
and be the Confidential Information of OBMP as the beneficial owner of the Vitel Shares. The provisions of this Clause
5.1(a) are in addition to, and separate from, any similar covenants and restrictions in respect of Confidential
Information to which a party hereto may be subject by reason of any employment or consulting relationship with OBMP and/or
Vitel (as applicable) or its Affiliates or the transactions contemplated herein.

 

    	 	26	 

    	 		 

    

 

(b)
“Confidential Information” shall mean any confidential or proprietary information relating to the business
or affairs of OBMP and/or Vitel or any of their Affiliates, including, but not limited to, information relating to financial
statements, customer identities, potential customers, employees, sales representatives, suppliers, servicing methods,
equipment programs, strategies and information, analyses, profit margins or other proprietary information used by OBMP and/or
Vitel or any of their Affiliates; provided, however, that Confidential Information does not include any information which is
in the public domain or becomes known in the industry through no wrongful act on the part of the a any of the parties hereto;
provided that Confidential Information shall not include information relating to OBMP and/or Vitel or any of their Affiliates
that (i) is or becomes generally known to the public other than as a result of a disclosure by the party hereto in violation
of this Agreement, (ii) is or was available to the party hereto on a non-confidential basis prior to its disclosure to the
party hereto, or (iii) was or becomes available to the party hereto on a non-confidential basis from a source other than OBMP
or Vitel, which source is or was (at the time of receipt of the relevant information) not bound by a confidentiality
agreement with OBMP or another person.

 

(c)
The parties hereto acknowledge that the success of Vitel after the date hereof depends upon the continued preservation of the
confidentiality of certain information possessed by the parties hereto, that the preservation of the confidentiality of such
information by such parties hereto is an essential premise of the bargain between MCO, CAV, and OBMP, and that the parties
hereto would be unwilling to enter into this Agreement in the absence of Clause 5.1(a). Accordingly, the parties
hereto agree that all information provided by or on behalf of OBMP to the parties hereto and their Affiliates and
representatives, together with all information provided by or on behalf of Vitel, MCO and CAV to OBMP and its Affiliates and
representatives in connection with the preparation of this Agreement shall be treated as “Confidential
Information” in accordance with the provisions of Clause 5.1(a).

 

Clause
5.2 Noncompete and Nonsolicitation. 

 

(a)
For a period of five (5) years from and after the date of this Agreement, neither MCO or CAV shall, or shall permit, cause or
encourage any of their Affiliates to, engage directly or indirectly, as an owner, employee, consultant, contractor or
otherwise, in any business or enterprise that is engaged in the development, commercialization, and/or sale of the OBMP
Products, the OBMP Pipeline Products or the Vitel Products (collectively the “Restricted Business”)
anywhere in the world as well as clinical development and marketing of therapeutic candidates similar to products that are
part of the Restricted Business anywhere in the world, except for those activities listed on Exhibit A as part of the
“Excluded Businesses”; provided, that no owner of less than 5% of the outstanding stock of any
publicly-traded corporation will be deemed to be so engaged solely by reason thereof in the Restricted Business. For a period
of five (5) years from and after the date of this Agreement, MCO and CAV shall not, and shall not permit, cause or encourage
any of their Affiliates to, solicit, recruit, offer employment, hire, employ, engage as a consultant, lure or entice away, or
in any other manner persuade or attempt to persuade, any Person who is an employee of any of OBMP or Vitel to leave the
employ of OBMP or Vitel. If the final judgment of a court of competent jurisdiction declares that any term or provision of
this Clause 5.2 is invalid or unenforceable, the parties hereto agree that the reduction in the scope, duration, or
area of the term or provision, or the deletion of specific words or phrases, or the replacement of any invalid or
unenforceable term or provision shall be carried out so as to include a term or provision that is valid and enforceable and
that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement will be
enforceable as so modified after the expiration of the time within which the judgment may be appealed.

 

    	 	27	 

    	 		 

    

 

(b)
Notwithstanding anything to the contrary in Clause 5.2(a) above, in no event shall MCO or CAV be prohibited from
engaging in any business under the following conditions:

 

MCO
or CAV (as applicable) shall promptly notify OBMP in writing of any business opportunities in any country or territory in the
world, with regard to any expansion of any business activity currently conducted by MCO or CAV beyond the Excluded Contracts so
long as such business (i) does not interfere with MCO or CAV’s duties under their employment agreements with Vitel and (ii)
does not compete with any of the products that are part of the Restricted Business anywhere in the world (the “ROW Opportunity”).
OBMP, when presented with an ROW Opportunity, shall have a period of thirty (30) days in which to decide to participate. In the
event the parties to the ROW Opportunity are unable to reach an agreement to consummate the transaction contemplated by the ROW
Opportunity within thirty (30) days, MCO and/or CAV shall be free to pursue the ROW Opportunity without OBMP or any of its Affiliates.

 

Clause 5.3 Amendments.
This Agreement may not be amended except by an instrument in writing signed on behalf of each of party.

 

Clause
5.4 Assignments. This Agreement and the rights and obligations hereunder shall not be assignable or transferable by any
party (including by operation of law in connection with a merger or consolidation of such party) without the prior written consent
of the other parties. Any attempted assignment in violation of this Clause 5. 3 shall be void.

 

Clause 5.5 Notices. All notices, requirements,
and requests associated with this Agreement may be made in writing. All notices shall be deemed duly given if they are given:
(a) in person, with return receipt; or (b) through a specialized courier service, with return receipt; or (c) via facsimile, upon
written confirmation of receipt thereof; or (d) by email, upon written confirmation of receipt thereof. All notices shall be given
to the following addresses, facsimile numbers or emails, and shall become effective once they are received, or when receipt thereof
is refused, as provided in the return receipt, or in the receipt of the specialized courier service:

 

	 	(a)	if
    to MCO:
	 	 	 
	 	 	Manuel
    Cosme
	 	 	Secretaria
    de Marina 700 Torre Bambu Depto 2301
	 	 	Lomas
    del Chamizal
	 	 	Del.
    Cuajimalpa
	 	 	CP.
    05120 Mexico
	 	 	Telephone:
    +52 55 1327 9067
	 	 	Facsimile:
    +52 55 5202 5854
	 	 	Email:
    mcosme@vitelpharma.com

 

    	 	28	 

    	 		 

    

 

	 	(b)	if
    to CAV:
	 	 	 
	 	 	Carlos
    Alaman
	 	 	Tabachines
    72
	 	 	Bosques
    de las Lomas
	 	 	Del.
    Cuajimalpa
	 	 	CP.
    05120 Mexico
	 	 	Telephone:
    +52 55 5257 0848
	 	 	Facsimile:
    +52 55 5202 5854
	 	 	Email:
    calaman@vitelpharma.com
	 	 	 
	 	(c)	if
    to OBMP:
	 	 	 
	 	 	Oncbiomune
    Pharmaceuticals, Inc. 
	 	 	11441
    Industriplex Blvd., Suite 190
	 	 	Baton
    Rouge, LA 70809 USA
	 	 	Attention:
    Andrew Albert Kucharchuk
	 	 	Telephone:
    225-227-2384
	 	 	Facsimile:
    225 227-2957
	 	 	Email:
    akucha1.OBMP@gmail.com 
	 	 	 
	 	 	With
    a copy (which shall not constitute notice) to:
	 	 	 
	 	 	Legal
    & Compliance, LLC
	 	 	330
    Clematis Street, Suite 217
	 	 	West
    Palm Beach, FL 33401
	 	 	Attention:
    Lazarus Rothstein, Esq.
	 	 	Telephone:
    561-433-6217
	 	 	Facsimile:
    561-514-0832
	 	 	Email:
    lrothstein@legalandcompiance.com

 

Clause
5.6 Exhibits and Headings. All documents attached hereto, or that are referenced herein, are incorporated by reference,
and shall form an integral part of this Agreement. If there is a conflict between this Agreement and such documents, this Agreement
shall govern. The titles and headings included in this Agreement are used solely for convenience purposes, and shall not define,
limit, or describe in any way the scope, or intent (or otherwise affect the construction) of any provision of this Agreement.

 

Clause
5.7 Fees and Expenses. Each party shall pay its own costs and expenses incurred in connection with the preparation and
execution of this Agreement.

 

Clause
5.8 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Nevada,
without regard to the conflicts of laws rules of such state.

 

    	 	29	 

    	 		 

    

 

Clause
5.9 Arbitration. Any and all claims or controversies arising from or relating to, this Agreement, its interpretation, or
its alleged breach or enforcement, shall be resolved by binding arbitration before the American Arbitration Association (“AAA”)
according to the Commercial Arbitration Rules of the AAA then in effect (the “AAA Rules”). The arbitration
shall occur in New York, New York and the parties waive any objection to this choice of alternative dispute resolution, procedures
or venue. The parties shall each appoint a single arbitrator and such arbitrators shall agree upon a third arbitrator or, if no
agreement can be reached within fourteen (14) days after the AAA provides the list of names from its National Roster, the AAA
shall appoint the third arbitrator according to the AAA Rules then in effect. Any arbitration hereunder shall be conducted in
English and shall be completed within one hundred and eighty (180) days after appointment of the third arbitrator. The arbitrators
shall be authorized to award reasonable attorneys’ fees and costs to the prevailing party in the arbitration, and to include
such sum in the final arbitration award. The arbitrators may not award punitive, consequential or special damages. The arbitration
award may be confirmed as a judgment in any court having jurisdiction of the subject matter and parties.

 

Clause
5.10 Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY
LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT, THE RELATED AGREEMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY AND
THEREBY

 

Clause
5.11 Specific Enforcement; Cumulative Remedies. The parties hereto acknowledge that money damages may not be an adequate
remedy for violations of this Agreement and that any party, in addition to any other rights and remedies which the parties may
have hereunder or at law or in equity, may, in his or its sole discretion, apply to a court of competent jurisdiction for specific
performance or injunction or such other relief as such court may deem just and proper in order to enforce this Agreement or prevent
any violation hereof and, to the extent permitted by applicable law, each party waives any objection to the imposition of such
relief. Process in any such suit, action or proceeding may be served on any party anywhere in the world, whether within or without
the jurisdiction of any such court. Without limiting the foregoing, each party agrees that service of process on such party as
provided in Clause 5.5 shall be deemed effective service of process on such party. All rights, powers and remedies provided
under this Agreement or otherwise available in respect hereof at law or in equity shall be cumulative and not alternative, and
the exercise or beginning of the exercise of any thereof by any party shall not preclude the simultaneous or later exercise of
any other such rights, powers or remedies by such party.

 

Clause
5.12 Entire Agreement. This Agreement and any exhibits and other documents referred to herein constitute the entire agreement
and understanding among the parties hereto in respect of the subject matter hereof and thereof and supersede all prior and contemporaneous
agreements and understandings, both oral and written, among the parties hereto, or between any of them, with respect to the subject
matter hereof and thereof.

 

    	 	30	 

    	 		 

    

 

Clause
5.13 Severability. If any term, provision, covenant or restriction of this Agreement or the application thereof to any
Person or circumstance is held by a court of competent jurisdiction or other authority to be invalid, void, illegal, unenforceable
or against regulatory or public policy to any extent, such term, provision, covenant or restriction shall be deemed modified to
the limited extent necessary for such term, provision, covenant or restriction to no longer be invalid, void, illegal, unenforceable
or against regulatory or public policy and to achieve the maximum intent of the parties, and the remainder of this Agreement and
the application thereof shall not be affected and shall be enforceable to the fullest extent permitted by law.

 

Clause
5.14 Counterparts; Effectiveness. This Agreement may be executed in any number of counterparts, each of which shall be
deemed to be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement
will become effective when duly executed and delivered by each party hereto. Counterpart signature pages to this Agreement may
be delivered by facsimile or electronic delivery (i.e., by email of a PDF signature page) and each such counterpart signature
page will constitute an original for all purposes.

 

Clause
5.15 Binding Agreement. Each and all of the covenants, terms, provisions and agreements contained in this Agreement shall
be binding upon and inure to the benefit of the parties and their respective heirs, executors, successors and permitted assigns.

 

IN
WITNESS WHEREOF, the parties enter into and execute this Agreement through their respective duly authorized legal representatives,
on the date mentioned in the preamble.

 

[The
rest of the page is intentionally left blank. Signature pages follow.]

 

    	 	31	 

    	 		 

    

 

Signature
page for the Contribution Agreement dated March 10, 2017, entered into by and between Manuel Cosme Odabachian, Carlos Fernando
Alaman Volnie and Oncbiomune Pharmaceuticals, Inc. 

 

By:
/s/ Manuel Cosme Odabachian

Name:
Manuel Cosme Odabachian

On
his own behalf

 

By:
/s/ Carlos Fernando Alaman Volnie 

Name:
Carlos Fernando Alaman Volnie

On
his own behalf

 

[The
rest of the page is intentionally left blank. Signature pages follow.]

 

    	 	32	 

    	 		 

    

 

Signature
page for the Contribution Agreement dated March 10, 2017, entered into by and between Manuel Cosme Odabachian, Carlos Fernando
Alaman Volnie and Oncbiomune Pharmaceuticals, Inc. 

 

ONCBIOMUNE
PHARMACEUTICALS, INC

 

By:
/s/ Andrew A. Kucharchuk

Name:
Andrew A. Kucharchuk

Its:
Attorney-in-fact

 

[The
rest of the page is intentionally left blank.]

 

    	 	33	 

    	 		 

    

 

EXHIBIT
A

 

ACTIVITIES
NOT SUBJECT TO NON-COMPETE

 

The
following business activities shall be deemed Excluded Businesses, as provided for in this Agreement so long as such business
activity (i) is currently conducted by MCO or CAV pursuant to the terms of any contract or agreement (the “Excluded Contracts”)
as in effect as of the date hereof and for so long as such contract or agreement is in effect, without any amendment to or renewal
of such contract or agreement after the Closing; (ii) does not interfere with MCO or CAV’s duties under their employment
agreements with Vitel, and (iii) does not compete with any of the products that are part of the Restricted Business anywhere in
the world (collectively, the “Excluded Business”):

 

	 	-	Clinical
    trials & contract research organization (CRO) services in Mexico.
	 	 	 
	 	-	Regulatory
    affairs consulting services and third party lobbying for sanitary registrations in Mexico.
	 	 	 
	 	-	Warehousing
    and/or hosting of pharmaceutical, biological, over-the-counter (OTC), supplements, medical devices and other health care products
    in Mexico.
	 	 	 
	 	-	Distribution
    of pharmaceutical, biological, OTC, supplements, medical devices and other health care products to the private and/or government
    segment in Mexico.
	 	 	 
	 	-	Manufacturing
    and development of branded generics, cosmetic, medical devices and private labels throughout Mexico.
	 	 	 
	 	-	Consulting
    services to international and Mexican companies in the healthcare market.
	 	 	 
	 	-	Consulting
    for the sale, license, acquisition for Mexican and/or foreign companies in Mexico.

 

    	 	 	 

    	 		 

    

 

Execution
Version

 

SCHEDULE
3.1 (i)

 

List
of actions, proceedings, arbitrations, investigations or audit, whether civil, criminal, administrative or judicial action pending
or threatened, against or involving MCO and CAV or Vitel as of the date of the Contribution Agreement:

 

None

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (j)

 

List
of equity interest or ownership stake in any Person that are directly or indirectly owned by Vitel:

 

1.
50% stake in Oncbiomune México, S.A. de C.V.

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (k)

 

True
and complete list of assets and liabilities of Vitel as of February 28, 2017

 

	VITEL LABORATORIOS, S.A. DE C.V.
	Assets and Liabilities as of February 28, 2017
	 
	Assets	 	 	 	 	 	 	 	Liabilities	 	 	 	 	 
	Current Assets	 	 	 	 	 	 	 	Current Liabilities	 	 	 	 	 
	Cash and Bank Accounts	 	$	959,176.27	 	 	 	 	Various Creditors	$	8,432,422.66	 	 	 
	Various Debtors	 	$	54,827.08	 	 	 	 	Payable Taxes	$	122,420.90	 	 	 
	Clients	 	$	3,481,318.52	 	 	 	 	 	 	 	 	 	 
	Recoverable Taxes	 	$	973,899.12	 	 	 	 	Sum of Current Liabilities	 	 	 	$	8,554,843.56
	Sum of Current Assets	 	 	 	 	$	5,469,220.99	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Fixed Assets	 	 	 	 	 	 	 	 	 	 	 	 	 
	Computer Equipment	 	$	10,200.00	 	 	 	 	Total Liabilities	 	 	 	$	8,554,843.56
	Sum of Fixed Assets	 	 	 	 	$	10,200.00	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	Deffered Assets	 	 	 	 	 	 	 	 	 	 	 	 	
	Payments in advance	 	$	-	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	Sum of Deferred Assets	 	 	 	 	$	-	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	Total Assets	 	 	 	 	$	5,479,420.99	 	 	 	 	 	 	

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (m)

 

Material
Adverse Effects known to Vitel:

 

None

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (n)

 

List
of all real property owned or leased by Vitel and all real property leases, surveys, encumbrances:

 

	 	1.	Mexico
    City Offices: Monte Pelvoux 130 Piso 3, Lomas de Chapultepec, Código Postal 11000, Delegación Miguel Hidalgo,
    Ciudad de México, México.
	 	 	 
	 	2.	Mexico
    Warehouse: Km. 14.5 s/n exterior, Col. San Antonio La Isla, Estado de México, México, C.P. 52280.

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (q)

 

List
of Material Contracts to which Vitel is a party.

 

	 	1.	Exclusive
    distribution and licensing agreement entered by and between AqVida GmbH and Vitel Laboratorios, S.A. de C.V. on June 17, 2016.
    By means of this agreement, AqVida GmbH granted in favor of Vitel Laboratorios, S.A. de C.V. an exclusive distribution license
    for certain products in Mexico. 
	 	 	 
	 	2.	Distribution
    and supply agreement entered by and between Laboratorios Q Pharma SL and Vitel Laboratorios, S.A. de C.V. on February 10,
    2016. By means of this agreement, Laboratorios Q Pharma SL appointed Vitel Laboratorios, S.A. de C.V. as its exclusive distributor
    for certain products in Mexico.
	 	 	 
	 	3.	Distribution
    Agreement entered by and between Roha Arzneimittel GmbH, Schwabe México, S.A. de C.V. and Vitel Laboratorios, S.A.
    de C.V. on August 29, 2016. By means of this agreement, Roha Arzneimittel GmbH appointed Vitel Laboratorios, S.A. de C.V.
    as its exclusive distributor to promote, market, distribute bud for public contracts and sell certain products in Mexico.
	 	 	 
	 	4.	Distribution
    Agreement entered by and between Roha Arzneimittel GmbH and Vitel Laboratorios, S.A. de C.V. on August 17, 2016. By means
    of this agreement, Roha Arzneimittel GmbH appointed Vitel Laboratorios, S.A. de C.V. as its distributor for certain products
    in Mexico.
	 	 	 
	 	5.	Distribution
    Agreement entered by and between Kamada Ltd. and Vitel Laboratorios, S.A. de C.V. on April 7, 2016. By means of this agreement,
    Kamada Ltd. appointed Vitel Laboratorios, S.A. de C.V. as its distributor for certain products in Mexico.
	 	 	 
	 	6.	Shareholders’
    Agreement entered by and between OncBioMune México, S.A. de C.V., OncBioMune Pharmaceuticals Inc. and Vitel Laboratorios,
    S.A. de C.V. on August 19, 2016. By means of this agreement, OncBioMune Pharmaceuticals Inc. and Vitel Laboratorios, S.A.
    set forth the terms and conditions for the operation of its Mexican subsidiary. 
	 	 	 
	 	7.	Services
    Agreement entered by and between Tercero Autorizado en Evaluación Sanitaria, S.C. and Vitel Laboratorios, S.A. de C.V.
    on April 27, 2016. By means of this agreement, Tercero Autorizado en Evaluación Sanitaria, S.C. shall provide evaluation
    services in accordance with the applicable sanitary laws in favor of Vitel Laboratorios, S.A. de C.V.
	 	 	 
	 	8.	Shareholders
    Agreement entered by and between OncBioMune Pharmaceuticals, Inc., and Vitel Laboratorios, S.A., dated August 19, 2016.
	 	 	 
	 	9.	Warehousing
    Agreement entered into by and between Bodegas Cero Grados, S.A. de C.V., in its capacity as custodian, and Vitel Laboratorios,
    S.A. de C.V., in its capacity as client, providing for merchandise warehousing services, dated May 16, 2016. 

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (r)

 

List
of claims and Material breaches involving Vitel:

 

None

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (t)

 

List
of all policies of fire and casualty, liability and other forms of insurance maintained by or on behalf of Vitel:

 

None

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (w)

 

List
of all valid, subsisting and in good standing Material governmental permits with respect to: (a) the ownership or use of Vitel’s
properties and/or; (b) the operation of the Vitel Business, in either case that are held by or for the benefit of Vitel:

 

	 	1.	Vitel’s
    Importer Registration (Padrón de Importadores) issued on January 19, 2017 by the Tax Service Administration
    (Servicio de Administración Tributaria)
	 	 	 
	 	2.	Operation
    Notice (Aviso de Funcionamiento) issued on June 2, 2016 by the The Federal Commission for the Protection against Sanitary
    Risk (Comisión Federal para la Protección contra Riesgos Sanitarios).

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (y)

 

Employee
benefit plans of Vitel:

 

None

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (hh)

 

List
of infringements or misappropriations of any intellectual property of Vitel:

 

None

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (jj)

 

List
of (1) Vitel Owned IP Rights (including all registrations of any patents, copyrights, mask works, trademarks, service marks, and
internet domain names, and all applications therefor), (2) Vitel Licensed IP Rights, (3) all applications, registrations, filings
and other formal written governmental actions made or taken pursuant to applicable law by Vitel to secure, perfect or protect
its interest in Vitel IP Rights and (4) all proceedings or actions before any governmental authority, including the Instituto
Mexicano de la Propiedad Industrial or equivalent authority anywhere else in the world related to any of Vitel IP Rights.

 

	File Number	 	 	Registration Number	 	Brand Name	 	Type	 	Description of the type of brand	 	Class	 	 	Owner
	1141583	 	 	1496892	 	VITEL	 	Brand Registration	 	NAME	 	 	1	 	 	Vitel Laboratorios, S.A. de C.V.
	1141586	 	 	1258305	 	VITEL	 	Brand Registration	 	NAME	 	 	35 36	 	 	Vitel Laboratorios, S.A. de C.V.
	1713067	 	 	In Progress	 	VITEL	 	Brand Registration	 	MIX / LOGO	 	 	35	 	 	Vitel Laboratorios, S.A. de C.V.
	1713074	 	 	In Progress	 	VITEL	 	Brand Registration	 	MIX / LOGO	 	 	5	 	 	Vitel Laboratorios, S.A. de C.V.
	1724616	 	 	In Progress	 	PROSCAVAX	 	Brand Registration	 	NAME	 	 	5	 	 	Vitel Laboratorios, S.A. de C.V.
	1730567	 	 	In Progress	 	ONCBIOMUNE	 	Brand Registration	 	NAME	 	 	35	 	 	Vitel Laboratorios, S.A. de C.V.
	1777475	 	 	In Progress	 	VIO PHARMACEUTICALS	 	Brand Registration	 	NAME	 	 	5	 	 	Vitel Laboratorios, S.A. de C.V.
	1777478	 	 	In Progress	 	VIO PHARMACEUTICALS	 	Brand Registration	 	NAME	 	 	35	 	 	Vitel Laboratorios, S.A. de C.V.

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (kk)

 

List
of royalties, honoraria, fees or other payments payable by Vitel to any third Person as a result of the use, license-in, manufacture,
sale, offering for sale, copying, distribution, or disposition of any Vitel Owned IP Rights by Vitel:

 

None

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (oo)

 

List
of all properties not owned or leased by Vitel and used in connection with the Vitel Business:

 

None

 

    	 	 	 

    	 		 

    

 

SCHEDULE
3.1 (pp)

 

List
of liabilities or contracts between: (i) Vitel, and (ii) MCO or CAV or any person who currently is serving, or has within the
past twenty-four months served, as an officer, director, or equity holder of Vitel:

 

None

 

    	 	 	 

    	 		 

    

 

Execution
Version

 

Schedule
3.2 (j)

 

List
of actions, proceedings, arbitrations, investigations or audit, whether civil, criminal,

administrative
or judicial action pending or threatened, against or involving OBMP.

 

None.

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (k)

 

List
of equity interest or ownership stake in any Person that are directly or indirectly

owned
by OBMP.

 

1.50%
stake in Oncbiomune Mexico, S.A. de C.V.

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (l)

 

True
and complete copies of the financial statements of OBMP as of September 30, 2016.

 

See
Financial Information included as part of Form 10-Q, filed with the SEC on November 21, 2016 for the quarterly period ending September
30, 2016.

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (n)

 

Material
Adverse Effects known to OBMP.

 

None.

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (o)

 

List
of all real property owned or leased by OBMP and all real property leases, surveys, encumbrances, and material documents relating
to such real property

 

	 	1.	Lease
    Agreement in connection with Baton Rouge facility, located at 11441 Industriplex Blvd., Suite 190, Baton Rouge, LA 70809.

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (r)

 

List
of Material Contracts to which OBMP is a party.

 

	 	1.	See
    agreements filed with SEC.

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (s)

 

List
of claims and Material breaches involving OBMP.

 

None.

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (u)

 

List
of all policies of fire and casualty, liability and other forms of insurance maintained by or on behalf of OBMP.

 

	 	1.	Business
    and Management Indemnity Policy (Scottsdale Insurance Company, Policy # EKS3199308)
	 	 	 
	 	2.	General
    Liability Policy (Scottsdale Insurance Company, Policy # CPS254548)
	 	 	 
	 	3.	Worker’s
    Compensation Policy (Louisiana Workers’ Compensation Corporation, Policy # 153175-A)

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (x)

 

List
of all valid, subsisting and in good standing Material governmental permits with respect to: (a) the ownership or use of OBMP’s
properties and/or; (b) the operation of the Vitel Business, in either case that are held by or for the benefit of OBMP.

 

 1. PGT/Vaccines:

 

	 	a.	See
    attached communications and certifications from the Department of Health and Human Services, Food and Drug Administration,
    in connection with the drug and drug-related items listed therein. 
	 	 	 
	 	b.	See
    chart of status of PGT and Vaccine Applications included as part of Schedule 3.2(kk).

 

2.
Authorization to do Business: OBMP is authorized to do business in Louisiana and Nevada.

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (z)

Employee
benefit plans of OBMP

 

OBMP
provides health insurance benefits as identified in:

 

1.
Humana # 748626-001

 

OBMP
pays 100% of employee family coverage cost.

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (ii)

 

List
of infringements or misappropriations of any intellectual property by OBMP.

 

None.

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (kk)

 

List
of (1) OBMP Owned IP Rights (including all registrations of any patents, copyrights, mask works, trademarks, service marks, and
internet domain names, and all applications therefor), (2) OBMP Licensed IP Rights, (3) all applications, registrations, filings
and other formal written governmental actions made or taken pursuant to applicable law by OBMP to secure, perfect or protect its
interest in OBMP IP Rights and (4) all proceedings or actions before any governmental authority, including the Instituto Mexicano
de la Propiedad Industrial or equivalent authority anywhere else in the world related to any of OBMP IP Rights.

 

		1.	Domain
                                         Names:

 

		a.	OncBioMune.com

 

		2.	Trademarks:

 

		a.	Pending
                                         application for mark “PROSCAVAX”

 

		3.	Patent
                                         / Drug IP: OncBioMune - Status of PGT and Vaccine Applications

 

	Docket
    No.	 	Country	 	Substatus	 	Appln.
    No.	 	Appln.
    Date	 	Patent
    No.	 	Grant
    Date	 	Title
	24412CA01	 	Canada	 	PENDING	 	2824347	 	01/09/2012	 	 	 	 	 	COMPOSITION
    AND METHOD FOR TREATING CANCER
	24412CN01	 	China
    P.R.	 	ALLOWED

        FEES
        PAID NOV. 2015
	 	201280005114.4	 	01/09/2012	 	TBD	 	TBD	 	COMPOSITION
    AND METHOD FOR TREATING CANCER
	24412EA01	 	Eurasia	 	PENDING	 	201370155	 	01/09/2012	 	 	 	 	 	COMPOSITION
    AND METHOD FOR TREATING CANCER
	24412EP01	 	Europe	 	INTENDED
                                         ALLOWANCE

        MAY
        15, 2016
	 	12701292.0	 	 	 	TBD	 	 TBD	 	COMPOSITION
    AND METHOD FOR TREATING CANCER
	24412HK01	 	Hong
    Kong	 	PENDING	 	14101607.7	 	02/20/2014	 	 	 	 	 	COMPOSITION
    AND METHOD FOR TREATING CANCER
	24412IN01	 	India	 	PENDING	 	6659/DELNP/2013	 	01/09/2012	 	 	 	 	 	COMPOSITION
    AND METHOD FOR TREATING CANCER

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

	Docket
    No.	 	Country	 	Substatus	 	Appln.
    No.	 	Appln.
    Date	 	Patent
    No.	 	Grant
    Date	 	Title
	24412JP01	 	Japan	 	PENDING	 	2013-549475	 	01/09/2012	 	 	 	 	 	COMPOSITION
    AND METHOD FOR TREATING CANCER
	24412MX01	 	Mexico	 	PENDING	 	MX/a/2013/008188	 	01/09/2012	 	 	 	 	 	COMPOSITION
    AND METHOD FOR TREATING CANCER
	24412UA01	 	Ukraine	 	ALLOWED

        INST.
        TO PAY FEES APR. 2015
	 	2013
    09855	 	01/09/2012	 	TBD	 	TBD	 	COMPOSITION
    AND METHOD FOR TREATING CANCER
	24412US01	 	United
    States	 	ISSUED	 	13/005993	 	01/13/2011	 	8647627	 	02/11/2014	 	COMPOSITION
    FOR A CANCER VACCINE
	24412US02	 	United
    States	 	ISSUED	 	14/137060	 	12/20/2013	 	 9211322	 	12/15/2015
    	 	COMPOSITION
    AND METHOD FOR TREATING CANCER
	24412US03	 	United
    States	 	PENDING	 	14/942517	 	11/16/2015	 	 	 	 	 	COMPOSITION
    AND METHOD FOR TREATING CANCER
	24413CA01	 	Canada	 	PENDING	 	2788663	 	01/31/2011	 	 	 	 	 	TAXANE-
    AND TAXOID- PROTEIN COMPOSITIONS
	24413EP01	 	EPC	 	PENDING	 	11702566.8	 	01/31/2011	 	 	 	 	 	TAXANE-
    AND TAXOID- PROTEIN COMPOSITIONS
	24413US02	 	United
    States	 	ALLOWED	 	13/017173	 	01/31/2011	 	TBD	 	TBD	 	TAXANE-
    AND TAXOID- PROTEIN COMPOSITIONS

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (ll)

 

List
of royalties, honoraria, fees or other payments payable by OBMP to any third Person as a result of the use, license-in, manufacture,
sale, offering for sale, copying, distribution, or disposition of any OBMP Owned IP Rights by OBMP.

 

None.

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (pp)

 

List
of all properties not owned or leased by OBMP and used in connection with the OBMP Business.

 

None.

 

    	 	 	 

    	 	 	 

    

 

Execution
Version 

 

Schedule
3.2 (pp)

 

List
of liabilities or contracts between: (i) OBMP and (ii) its current shareholders or any person who currently is serving, or has
within the past twenty-four months served, as an officer, director, or equity holder of OBMP.

 

	 	1.	Employment
    Agreement between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk effective as of February 2, 2016.
	 	 	 
	 	2.	Employment
    Agreement between OncBioMune Pharmaceuticals, Inc. and Jonathan F. Head, Ph.D. effective as of February 2, 2016.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]